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Abstract 
Prostate cancer (PC) is the most common cancer in men. In the UK alone, 
there are over 30,000 men diagnosed with PC every year. Loss of SPRY2 and 
activation of receptor tyrosine kinases are common events in PC. However, the 
molecular basis of their interaction and clinical impact remains to be fully 
examined. SPRY2 loss may functionally synergise with aberrant cellular signalling 
to drive PC and to promote treatment resistant disease. Using a combination of 
in vitro, pre-clinical in vivo models and clinical PC, this thesis shows the impact 
of SPRY2 loss upon activation of the ErbB signalling system via a positive 
feedback regulation of the ErbB-PI3K/AKT cascade. Loss of SPRY2 resulted in 
hyper-activation of PI3K/AKT signalling to drive proliferation and invasion by 
enhanced internalisation of EGFR/HER2 and their sustained localisation and 
signalling at the early endosome in a PTEN-dependent manner. This involves 
activation of p38 MAPK by PI3K to facilitate clathrin-mediated ErbB receptor 
endocytosis. Furthermore, this thesis suggests a critical role of PI3K/AKT in PC 
whereby in vitro and in vivo inhibition of PI3K suppresses proliferation and 
invasion, supporting PI3K/AKT as a target for therapy particularly in patients 
with PTEN-haploinsufficiency, low SPRY2 and ErbB expressing tumours. In 
conclusion, SPRY2 is an important tumour suppressor in PC; its loss drives the 
PI3K/AKT pathway via functional interaction with the ErbB system. 
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Chapter 1. Introduction 
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1. Introduction 
1.1 Prostate Cancer 
1.1.1 Natural history of prostate cancer 
 In 2007, there were around 36,100 men diagnosed with prostate 
cancer (PC) in the UK alone, and around 913,000 men were diagnosed with PC 
worldwide (CRUK 2010). Although the cancer death rate has decreased steadily 
since 1990s, prostate cancer remains the second most common cause of cancer 
death in UK men, after lung cancer. Such improvement in survival may be 
attributed to the increased use of prostate-specific antigen (PSA) testing. PSA, 
as a biomarker, revolutionised the diagnosis of prostate cancer. It allows the 
detection of prostate tumours at early stage, and the test procedure is easy and 
straightforward. Despite a vast increase in the diagnosis of PC, PSA testing is not 
able to differentiate between latent and life-threatening tumours reliably at the 
time of diagnosis. Patients with raised PSA levels typically undergo biopsy to 
assess the potential presence of cancerous disease. The biopsy samples are 
analysed according to the histopathological grading system called Gleason 
scoring, which classifies cancer from 1 to 5 based on histological appearance and 
tissue architecture (Mellinger et al., 1967, Epstein, 2010). In addition, patients 
are diagnosed with various stages based on the status of the primary tumours, 
including invasive disease (T1-4), lymph node involvement (N0-1), and 
metastatic PC (M0 and 1a-c) (Ohori et al., 1994, Falzarano and Magi-Galluzzi, 
2011). Once early prostate cancer is diagnosed, the conventional treatment in 
UK includes external beam radiation therapy, brachytherapy, surgery and active 
surveillance with intent for deferred intervention. In addition castration for the 
treatment of advanced prostate cancer was such an important advance in the 
clinic that earned Charles Huggins a Nobel Prize in 1966 (Huggins, 1967). 
Historically ancient Egyptians first described PC as a clinical disease, and 
surgical castration reduces initial tumour burden by depleting androgen level, 
but eventually results castration-resistant disease. Unfortunately, to date such 
advanced PC remains incurable; current docetaxel-based chemotherapy or PC 
vaccine only extends patient survival up to 3-4 months (Petrylak, 2005, Jathal et 
al., 2011). This highlights the critical need for improved molecular markers and 
   15 
other approaches by basic scientific research and preclinical models to 
complement the existing assessments of PC for more effective prognosis and 
treatment. 
1.1.2 Prostatic intraepithelial neoplasia (PIN) and metastatic prostate cancer 
Prostate cancer is widely considered as a progressive disease often 
involving sequential deregulation of molecular processes and pathways (Figure 
1.1.1). The progression was described as from normal epithelium to PIN, then 
more aggressive adenocarcinoma and metatstasis. In 1987 Bostwick and Brawer 
first proposed the term PIN to describe low grade PC (Bostwick and Brawer, 
1987). PIN is defined as a histological interpretation of cellular enhancement of 
the normal glandular architecture with cytological abnormality including 
enlargement of nuclei and nucleoli, and cytoplasmic hyperchromasia. PC is 
generally considered as a multifocal disease with formation of heterogenous foci 
and advanced metastasis to secondary organs. The heterogeneity is also 
observed in PIN with involvement of multiple clusters of glandular structures. In 
addition, the exhibition of increased cell proliferation markers in prostate is 
considered as high grade PIN (Bostwick, 1989, Shappell et al., 2004).  
 
Advanced PC often metastasises to distant organs including lung, liver and 
pleura. Interestingly, bone metastasis occurs inevitably with unknown reason in 
advanced PC patients, where it leads to osteoblastic lesions (Bubendorf et al., 
2000, Logothetis and Lin, 2005). Such complication in bones is incurable and a 
major cause of morbidity for advanced PC patients, which creates another level 
of clinical challenge. Recent studies detected circulating prostate tumour cells 
Prostatic intraepithelial neoplasia (PIN)
and prostate cancer
It is widely accepted that PIN represents a precursor for
prostate cancer, although this relationship has not been
demonstrated conclusiv ly (Bostwick 1989; DeMarzo et al.
2003). PIN is generally characterized at the histological
level by the appearance of luminal epithelial hyperplasia,
reduction in basal cells, enlargement of nuclei and nucleoli,
cytoplasmic hyperchromasia, and nuclear atypia; in addi-
tion, high-grade PIN lesions generally display marked
elevation of cellular proliferation markers (Bostwick
1989; Shappell et al. 2004). In contrast with prostate cancer,
however, basal cells are reduced in number in PIN, but are
not absent.
Although human prostate cancer displays significant
phenotypic heterogeneity, >95% of prostate cancers are
classified pathologically as adenocarcinoma, which has
a strikingly luminal phenotype (Fig. 2). In biopsy speci-
mens, prostate adenocarcinoma diagnosis can be con-
firmed by the absence of immunostaining using p63 and
cytokeratin 5/14 antibodies, both of which detect basal
cells (Humphrey 2007; Grisanzio and Signoretti 2008). In
addition, a diagnosis of prostate cancer is supported by
elevated immunostaining for a-methylacyl-CoA race-
mase (AMACR), a luminal marker that is overexpressed
in carcinoma (Luo et al. 2002; Jiang et al. 2005; Humphrey
2007). Similarly, prostate cancer arising in many mouse
models displays a relatively luminal phenotype (Kim et al.
2002d; X M et al. 2005). However, the overt histological
appearance of prostate carcinoma in most genetically
engineered mouse models often differs from that of
typical human prostate cancer (Fig. 2).
Subtypes of prostate cancer
A notable difference between prostate cancer and other
epithelial tumors, such as breast cancer, is the lack of
distinguishable histopathological subtypes that differ in
their prognosis or treatment response. The vast majority
of prostate cancers correspond to acinar adenocarcinomas
that express AR, while other categories of prostate
cancer—such as ductal adenocarcinoma, mucinous car-
cinoma, and signet ring carcinoma—are extremely rare
Figure 1. Progression pathway for human prostate cancer. Stages of progression are shown, together with molecular processes and
genes/pathways that are likely to be significant at each stage. Adapted from Abate-Shen and Shen (2000).
Figure 2. Histopathology of human and mouse
prostate cancer. (A–D) Hematoxylin-eosin-stained
sections of human prostate. (A) Benign normal
tissue, with representative basal (bas) and luminal
(lum) cells indicated. (B) PIN; arrows indicate
regions of hyperplastic epithelium. (C) Well-dif-
ferentiated adenocarcinoma. (D) Poorly differenti-
ated adenocarcinoma. (E–H) Hematoxylin-eosin-
stained sections of anterior prostate from geneti-
cally engineered mouse models. (E) Normal
tissue, with characteristic papillary tufting (arrow-
heads). (F) High-grade PIN. (G) Prostate carci-
noma. (H) Prostate carcinoma with an invasive phenotype. We thank Dr. Robert Cardiff and Alexander Borowsky (School of Medicine,
University of California at Davis) for providing images of human prostate specimens.
Shen and Abate-Shen
1970 GENES & DEVELOPMENT
Figure 1.1.1 Stages of human prostate cancer progerssion. Adopted 
from Abate-Shen and Shen (2000)   
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in the bone marrow and peripheral blood (Pantel and Alix-Panabieres, 2010). 
However, disseminated tumour cells were also found in patients with localised 
disease, which suggests the limited capability to metastasise at the early stage 
of the disease. Yet, the circulating tumour cells within metastatic disease 
consisted of multiple chromosomal rearrangements comparable with typical 
advanced PC (Attard et al., 2009, Holcomb et al., 2008, Leversha et al., 2009). 
Despite the clinical importance of tumour metastasis, the molecular mechanisms 
involved in promoting this process remains to be resolved. Furthermore, recent 
genomic analysis (Taylor et al., 2010) have provided a great deal of insight into 
the molecular signature of PC, which allows us to distinguish subtypes of PC and 
stratification of patients according to gene expression and copy number 
alteration.  
1.1.3 Mouse model of prostate cancer 
Mouse models have provided an extremely useful research platform to 
study PC including, xenograft, tissue reconstitution and genetically engineered 
models. In vivo PC studies are often carried out by implanting human PC cell 
lines in immunodeficient mice orthotopically or transplanting into the flank. The 
xenograft models provided a great insight into the molecular mechanisms 
involved in carcinogenesis and chemotherapeutic strategies. However there are 
major limitations to the xenograft models, notably the absence of a 
heterologous microenvironment associated with PC; inability to analyse the 
effect of the immune system and the restriction to using clonal cell lines. In 
order to manipulate specific genes in both mouse and human prostate tissue, 
tissue reconstitution models are employed to investigate not only prostate 
organogenesis but also prostate tumorigenesis in vivo. This procedure often uses 
immortalised human or mouse prostate cells, which can reconstitute relatively 
normal (histology) prostate tissue. The gene of interest can be overexpressed or 
knocked down in vitro, and the subsequent phenotypes in vivo analysed. Such 
methods also allow us to study stromal compartments using cancer associated 
fibroblasts, and assess genes that give lethal embryonic phenotypes.  
Development of transgenic mouse models for prostate cancer has 
provided another useful approach to investigate prostate tumorigenesis and to 
recapitulate human disease. To date, there are a handful of genetically 
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engineered mouse models for PC. The first transgenic PC mouse model was 
generated by Greenberg using potent viral oncogenes (Greenberg et al., 1995). 
The TRAMP (transgenic adenocarcinoma of the prostate) mouse model developed 
an aggressive disease with neuroendocrine differentiation, which however is 
rarely observed in human PC (Shappell et al., 2004). Nonetheless, the first-
generation of transgenic mouse model provided important insight into the 
disease progression and investigation of castration resistant disease. In order to 
target specifically prostate tissue, probasin and PSA promoters were used to 
drive candidate gene expression. The application of such approach to loss-of-
function mutations in the genes of interest has led to the second-generation of 
mouse models. There are few popular choices of models including Nkx3.1, Pten, 
Pb-Cre4, and Nkx3.1-Cre transgenes.  
Nkx 3.1 is a homeobox gene, which is shown to be involved in prostatic 
epithelial development and differentiation. Loss of Nkx3.1 gene leads to 
hyperplastic lesions in anterior, dorsolateral prostate and stroma regions, but 
the ventral prostate appears to be normal in 1-2 year old mouse model. Also in 
prostate cell lines including PC3 and AT6 was observed decreased cell 
proliferation when Nkx3.1 was overexpressed (Sciavolino et al., 1997, Kim et al., 
2002a, Kim et al., 2002b). This suggested that the Nkx3.1 gene has a potential 
tumour suppressive role. Both loss of Nkx 3.1 gene and epigenetic silencing of 
the gene have been detected in human prostate cancer (Emmert-Buck et al., 
1995, Voeller et al., 1997). However, the homozygous deletion of Nkx3.1 seems 
to only develop PIN phenotype with few layered epithelium and enlarged 
nucleoli but not extreme pleomorphism, and never progress into 
adenocarcinoma or metastatic disease. Given PC is a multistep process, 
combination of candidate tumour suppressor genes and oncogenes in mouse 
models have provided great insight into the molecular mechanisms involved in 
prostate carcinogenesis. Pten is one of the most commonly mutated tumour 
suppressor genes in human cancer, and Pten heterozygous mutant mice develop 
high grade PIN with incomplete penetrance, and the phenotype is closely related 
to the subtle Pten dosage in the mouse model (Carracedo et al., 2011b). Kim and 
his colleagues further investigated the cooperation of Nkx3.1 and Pten in mouse 
prostate. The double homozygous mutants displayed localised severe dysplastic 
lesions with higher penetrance in comparison with single mutant Pten or Nkx3.1 
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heterozygous mice. However, there was no difference in survival profile 
between double and single mutants. High-grade PIN was observed with Nkx3.1-/-; 
Pten+/- prostates. This suggests the cooperation of tissue specific genes and 
common tumour suppressor genes can contribute to the tissue specific cancer 
progression. Furthermore, Tomlins and his colleagues discovered for the first 
time recurrent chromosomal rearrangement in human prostate cancer, which 
involves two ETS transcription factors (ERG and ETV1) and 5’ untranslated region 
of TMPRSS2 (Tomlins et al., 2005). This study led to the generation of the 
TMPRSS2-ERG fusion mouse model, and the transgene positive mice developed 
dysplasia in prostate (King et al., 2009a). It suggested that such simple mutation 
might not sufficient for the initiation and progression of the PC. However, 
combination of Pten+/- and the TMPRSS2-ERG fusion mice developed PIN at 6 
months with invasive phenotype, suggesting the cooperation between PI3K 
signalling pathway and ERG in the PIN development. Interestingly, the 
combination of different gene sets have demonstrated the development of PIN in 
mouse model, but these events alone could not progress into aggressive 
malignancies observed in human prostate. Recent intergrated genomic analysis 
of human PC suggests that additional mutational events are required for the 
development of prostate carcinoma in preclinical mouse model. Yet, as the 
complexity of mutations increase in mouse model, the accurate analysis and 
interpretation of mechanisms involved in the progression of the diseases become 
a great challenge.  
 
1.1.4 Molecular mechanisms of prostate cancer initiation and progression 
Recent progress in the genetically engineered mouse models and in vitro 
studies have significantly advanced our understanding of molecular mechanisms 
involved in prostate carcinogenesis. Patients with advanced PC are often treated 
with androgen deprivation therapy, which is performed either with the 
administration of drug using anti-androgens including bicalutamide, or surgical 
castration. AR plays a critical role in normal prostate development as well as 
prostate carcinogenesis. The Leydig cells within the testis synthesise the ligand 
testosterone acting as androgen, which is converted into its more active form 
dihydrotestosterone in prostatic cells. AR is a member of steroid nucleus 
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receptor, and acts as a transcription factor upon ligand binding. The best 
characterised and clinically implicated AR target gene is KLK3, which encodes 
PSA protein. The androgen depletion therapy initially leads to rapid regression of 
androgen-dependent prostate tissue via apoptosis, which is also induced by 
stromal tissue. The function of stroma was evident in tissue reconstitution 
experiments with androgen dependent cell lines, which undergo apoptosis 
following withdrawal of androgen. These cell lines showed reduced proliferation 
when androgen was not present, but not apoptosis when grown without stromal 
components (Gao et al., 2001, Kurita et al., 2001). Due to the selection 
pressure, PC eventually develops into a castration resistant state, which may 
involve AR mutation or increase in androgen synthesis. Castration resistant 
tumour cells employ various interesting ways to adapt and survive in AR 
withdrawn environment. The most common AR reactivation mechanisms are 
amplication/overexpression of AR, constitutively activating mutation, aberrant 
post-translational modification, and alternative splicing. For instance, 
approximately over 30% patients with castration-resistant disease show 
amplification of AR genes (Linja et al., 2001). Another common mechanism 
found in PC patients consists of gain of function mutation leading to more 
stable, greater sensitivity to the ligands or constitutive activation of the 
receptor with alternative splicing variant (Guo et al., 2009, Steinkamp et al., 
2009, Brooke et al., 2008). 
Another receptor family including ErbB is shown to interact with AR 
signalling cascade and stimulate prostate cancer cell survival. ErbB family 
members consist of ErbB1 (EGFR), ErbB2 (HER2), ErbB3 (HER3) and ErbB4 (HER4), 
which are essential for developmental process and tumour progression. Although 
there are no mutations of ErbB receptors identified in prostate cancer, crosstalk 
between AR and ErbB signalling and contribution to castration resistant PC 
progression was reported in recent years. EGFR and ErB2 expression was 
controlled by AR c-terminal domain and RTK are essential for cell proliferation in 
PC cell lines (Pignon et al., 2009). ErbB2 is also implicated in castration resistant 
PC through AR dependent DNA binding and its stablisation (Mellinghoff et al., 
2004). Given the important role of ErbB signalling in PC progression and the 
successful outcome in targeting ErbB as treatment for breast cancer, various 
chemotherapies against EGFR and HER2 were tested in preclinical models and PC 
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patients. Currently, there are several tyrosine kinase inhibitors (TKI) and 
monoclonal antibodies developed for clinical trials, these include HER2-directed 
antibody trastuzumab, EGFR inhibitors (erlotinib and gefitinib) and EGFR-
directed monoclonal antibodies (cetuximab and panitumumab). Despite report of 
these TKI and monoclonal antibodies inhibiting cell proliferation in vitro and in 
xenograft models (Tomlins et al., 2005), phase II clinical trials on patients with 
advanced PC indicated no significant effect neither in PSA levels nor survival 
benefit (Gross et al., 2007, Morris et al., 2002, Salzberg et al., 2007). These 
disappointing results can be explained by the effect of the redundant ErbB 
family members and their complex signalling network. Also RTK amplication does 
not occur as often as in breast and lung cancer.  
PTEN (phosphatase and tensin homolog located on chromosome10) is 
among the most frequently mutated or deleted tumour suppressor genes in 
human cancers, and was first identified in breast and PC (Li et al., 1997, Steck 
et al., 1997). PTEN is encoded on chromosome 10q23, and consists of a 
phosphatase domain, C2 or lipid membrane-binding domain, C-terminal region 
and PDZ-binding domain (Figure 1.1.2).  PTEN is well known for its negative 
regulatory role in PI3K/AKT signalling pathways via dephosphorlation of the 3-
phosphoinositide. The PI3K/AKT pathway is an important regulator of cell growth 
and survival. The exact status of PTEN deregulation in PC was unclear until 
recent multiple research approaches. The main questions were whether PTEN 
alleles were both deleted or only one allele is lost and the other one is mutated, 
or the expression is affected. After a long-standing debate, it is accepted that 
PTEN undergoes copy number loss at the early stage of carcinogenesis, and 
complete loss of PTEN occurs at a relatively late stage of PC progression, 
including aggressive, and castration-resistant disease (Taylor et al., 2010). 
Pandolfi and colleagues asked an intriguing question regarding the relationship 
between subtle PTEN expression level and cancer susceptibility (Carracedo et 
al., 2011a). It is well known that a complete loss of PTEN bypass cellular 
senescence in prostate mouse model, and becomes a hallmark of advanced 
human PC. The PC genomic cBio portal showed that only 7% of PC patients 
harboured complete loss of PTEN, which means the majority of cases still retain 
normal or low PTEN expression level (Taylor et al., 2010). 
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Indeed, it is important to address the importance of subtle reduction of 
PTEN in prostate carcinogenesis and other tumours. Interestingly, hypomorphic 
PTEN mouse model with PTEN expression level between heterozygous and 
knockout resulted in a full penetrance PC with invasive phenotype (Trotman et 
al., 2003b). Furthermore, there are also other tumour suppressor genes, which 
exert their inhibitory function through PTEN, including Sprouty family members 
(Edwin et al., 2006). This suggests an interesting idea that subtle PTEN reduction 
can have a dramatic impact in carcinogenesis. In addition to the membrane 
PTEN tumour suppressor role, recent reports suggest an interesting function of 
nuclear PTEN in cell cycle arrest, genomic instability, differentiation, and gene 
expression. In the nucleus, the phosphatase domain seems to not play a crucial 
role regarding nucleus PTEN enzymatic activities (Lindsay et al., 2006). On the 
basis of these studies, the membrane PTEN is merely one aspect of PTEN 
function in various cellular compartments.   
PTEN deficient PC results in abnormal activation of PI3K/AKT signalling 
pathway (Thomas et al., 2004). The canonical PTEN/PI3K/AKT pathway is 
initiated from the activation of receptor tyrosine kinases (RTK), such as EGFR, 
and ERBB2. When PTEN expression is decreased or absent, products of PI3K 
activates AKT via its upstream kinase PDK1 in an uncontrolled manner. There are 
many downstream targets for AKT including GSK3, p27, p21, mTOR and FOXO, 
which are responsible for cell cycle progression, invasion and proliferation. 
mTOR also activates AKT in reciprocal feedback loop in PTEN deficient cancer 
cells. Given the importance of PTEN/PI3K/AKT signalling pathway, there are 
many candidate drugs developed to target mTOR or PI3K or as dual inhibitors. 
However, tumour cells evolve to adopt other kinase signalling pathways, 
including MAPK cascades, and consequently resulting in more aggressive drug 
resistant disease. Using combinatory therapy to target such parallel networks 
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phosphorylation, ubiquitylation, oxidation, acetylation, 
proteosomal degradation and subcellular localization 
(reviewed in REFS 34,35). Although many of these post-
translational changes in PTEN have been shown to alter 
various cellular phenotypes in vitro, most have not been 
validated as key regulators of PTEN in human cancer 
or mouse models. PTEN amino acids Lys13 and Lys289 
are monoubiquitylated, which leads to nuclear import 
in vitro, and Lys289 mutations have been observed in 
Cowden syndrome and associated with nuclear exclu-
sion36. No Lys289 mutations have been reported in 
sporadic cancers, although Lys13 mutation was found 
in four of 632 endometrial cancers (see the COSMIC 
database; see Further information).
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Germline PTEN mutation in Cowden syndrome can 
lead to decreased or absent expression or activity of the 
mutant allele. Initial efforts to model Cowden syndrome 
in mice used genetic deletion of a single allele of Pten, as 
loss of both alleles is embryonic lethal. These Pten 
heterozygous (Pten+/–) mice recapitulated some of 
the neoplastic phenotypes observed in patients with 
Cowden syndrome, such as breast and endometrial 
tumours and intestinal polyps37–39. However, the genetic 
background of Pten+/– mice is a strong determinant of 
susceptibility to specific tumour types (BOX 1). Some 
strains exhibit tumour types that are not typically asso-
ciated with Cowden syndrome, such as prostate and 
adrenal tumours and lymphoma40, whereas other strains 
show a reduced incidence of tumours types that are nor-
mally associated with Cowden syndrome, such as breast 
and endometrial tumours41. Decreasing PTEN dosage 
has been shown to correlate with increasing tumour 
formation in mice, supporting the value of Pten+/– mice 
as models for Cowden syndrome.
Somatic PTEN alteration is common in many 
sporadic tumour types42, some of which also occur 
with germline PTEN alteration in Cowden syndrome 
(TABLE 1). This suggests that PTEN alteration may be an 
aetiological factor in these tumour types. Various tissue-
specific and/or inducible homozygous deletions of Pten 
have been generated in mice to model sporadic PTEN 
loss in tumorigenesis. In the endometrium43, mammary 
gland44 and prostate45, and in T cells46, homozygous dele-
tion of Pten led to rapid tumour formation in the tar-
geted tissue. Tumours took longer to develop after Pten 
deletion in the liver47, bladder48 and lung49. By contrast, 
when Pten was deleted in pancreatic β-cells50 or the 
intestine51, no malignant tumours developed, although 
intestinal polyps were common, as observed in Cowden 
syndrome. Loss of other tumour suppressors or the 
activation of oncogenes can nonetheless combine with 
PTEN loss to cause cancer in these organs. The follow-
ing sections describe the intersection of PHTS, sporadic 
cancer and mouse models to delineate the role of PTEN 
alteration in specific cancers.
Breast cancer. Female patients with Cowden syndrome 
have a high risk (an estimated 25–50% risk) of developing 
breast cancer over the course of their lifetime, and male 
patients with Cowden syndrome are also thought to be 
at an increased risk52. PTEN loss can also occur in other 
populations at a high risk of breast cancer, such as those 
that carry germline mutations in BRCA1 in which PTEN 
deletions have been described53, and can also occur in 
those at an indeterminate risk. For example, despite the 
fact that less than 5% of sporadic breast tumours har-
bour PTEN mutations, loss of PTEN immunoreactivity is 
observed in nearly 40%54. This highlights the importance 
of immunohistochemistry methodology in determining 
PTEN status55. Moreover, about 40% display loss of heter-
ozygosity (LOH) at 10q23 (REF. 56), and aberrant promoter 
methylation was identified in nearly 50% of tumours25. 
As PTEN loss and ERBB2 mutations both activate the 
AKT signalling pathway, perhaps it is not surprising that 
many tumours that exhibit loss of PTEN are also oestrogen 
receptor (ER)-positive and ERBB2-negative54.
Pten+/– mice can develop mammary tumours at high 
frequencies depending on their genetic background39. 
Deletion of both Pten alleles in the mammary epithe-
lium leads to altered mammary development and high-
frequency, early-onset tumours in mice44. Loss of a single 
Pten allele accelerated tumorigenesis in a Wnt-induced 
mammary tumour model, and most tumours lost the 
remaining Pten allele57. Similar results were observed 
when breast-specific Pten deletion was coupled with 
overexpression of Erbb2 (REF. 58). In two other models, 
subtle decreases in PTEN expression increased the risk 
of tumour formation in the absence of any other intro-
duced mutations22,23. These mouse studies suggest that 
decreased PTEN expression leads to an increased risk of 
breast tumour formation. Attenuated PTEN expression 
by gene mutation, LOH or promoter methylation may 
indeed be a driving alteration in breast cancer, making 
PTEN signalling pathways or pathways downstream 
of PTEN potential targets for breast cancer therapy.
Endometrial cancer. The lifetime risk of endometrial 
cancer for patients with Cowden syndrome is estimated 
to be 5–10%52,59, and 35–50% of sporadic endometrial 
carcinomas have PTEN mutations (TABLE 1). Mutations 
in PTEN are also observed in endometrial hyperplasia, 
which is thought to be a precursor lesion for endometrial 
carcinoma60–62. Many endometrial tumours have short 
insertion or deletion frameshift mutations that are typical 
of microsatellite instability. In particular, PTEN frameshift 
mutations are observed in endometrial carcinomas that 
are associated with hereditary non-polyposis colon 
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Figure 1.1.2 Schematic of the PTEN protein. Adopted from Holla der, 
Blumenthal and Dennis (2011)   
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seemed more effective in a preclinical model with PTEN depletion and castration 
resistant PC (Gumerlock et al., 1997). 
Initially recurrent chromosomal rearrangements were discovered in 
haematological and mesenchymal neoplasm but rarely in solid tumours. 
However, recent studies identified that such events also occur in many epithelial 
cancers including PC. For instance, Tomlins (Tomlins et al., 2005) identified 
chromosomal rearrangement between the ETS family of transcription factors and 
TMPRSS2 gene, which creates TMPRSS2-ERG or TMPRSS2-ETV1 fusion genes in the 
majority (79%) of prostate cancer. TMPRSS2 is an androgen responsive gene 
loacated on the chromosome 21q, which activates the ETS family transcription in 
the case of the fusion gene. The mechanisms for chromosomal rearrangement at 
these loci were suggested as either an interstitial deletion or unbalanced 
interchromosomal translocation (Iljin et al., 2006, Perner et al., 2006). In 
addition, AR signalling cascade was shown to be involved in DNA damage by 
recruiting topoisomerase, which may be associated with chromosomal 
rearrangement at this site (Haffner et al., 2010). Recent genomic profiling and 
mouse model studies suggest that the functional effect of ETS family alone is 
moderate which lead to the development of a weak PIN phenotype (Tomlins et 
al., 2007). Addition of the PTEN deletion synergises with ETS to result in high 
grade PIN and carcinoma in mice (Carver et al., 2009, King et al., 2009b). Thus 
despite the identification of the chromosomal arrangement, the functional 
effect remains to be fully elucidated. The fusion genes may cooperate with 
other oncogenic events to promote prostate carcinogenesis. 
The first proposal of cancer stem cell (CSC) model in myeloid leukemia by 
John Dicks and colleagues became a paradigm for later studies in solid tumour 
CSC nearly a decade ago (Lapidot et al., 1994). The CSC was firstly identified in 
breast cancer as a solid tumour model, and represents a distinct population 
within the tumour (Visvader, 2009). CSC is generally defined as subsets of cells 
with self-renewal ability, which can produce many different types of cancer cells 
with more differentiated phenotype. Such ability may explain the heterogeneity 
of solid tumours particularly in PC. The origin of CSC is unclear may derive from 
the normal stem cells which accumulate mutations. For prostate cancer CSC 
field, there are still many questions to be answered. It is believed that the 
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localisation of prostate stem cells in the tissue is highly relevant to the origin of 
the CSC (Lawson and Witte, 2007). A glandular organ, the prostate consists of 
anatomically distinct epithelial cells including basal cells forming the basement 
of each prostatic duct, neuroendocrine cells in the basement layer along with 
the basal cells, and luminal cells lining the ductal lumens above the basal cells. 
Wang and his colleagues first characterised a rare population of prostate CSC 
called CARNs (castration resistant Nkx3-1-expressing cells) in an elegantly 
designed transgenic mouse model. CARNs represent a luminal stem cell 
population with bipotential and self-renewal in vivo, which generates high grade 
PIN with targeted PTEN loss (Wang et al., 2009). Yet, identification of prostate 
cancer cell-of-origin was reported with isolation of normal human prostate with 
basal cell characteristics, which is transplanted to induce adenocarcinoma 
formation with luminal phenotype in a reconstitution mouse model (Goldstein et 
al., 2010). Altogether, prostate cancer may involve distinct subtypes of CSC, and 
recent CSC models required PTEN deletion to progress into aggressive tumour. 
However the different molecular pathways involved in lineage progression to 
prostate cancer initiation remains to be elucidated. 
1.2 Sprouty and cancer: history of discovery  
Over a decade ago, the Sprouty (SPRY) family was discovered in a genetic 
screen while investigating genes involved in tracheal branching in Drosophila, 
owing its name to the ability to prevent excessive airway branching (Hacohen et 
al., 1998). The Drosophila SPRY protein was shown to be a general antagonist of 
several different receptor tyrosine kinases (RTK) (Casci et al., 1999, Kramer et 
al., 1999, Reich et al., 1999). Subsequently, multiple orthologues of SPRY 
proteins have been identified in zebrafish, Xenopus, mouse, chicken and human 
(Chambers and Mason, 2000, Furthauer et al., 2001, Minowada et al., 1999). 
There are four unique spry genes identified in mammals to date. The mouse and 
human SPRY (SPRY 1-4) genes encode 32-34 kDa proteins that are considerably 
smaller in size than Drosophila SPRY (63 kDa) (Figure 1.2.1). The mammalian 
SPRY family members consist of divergent sequence at their amino termini, 
which may dictate their differential functions. The conserved cysteine-rich 
domain is located at the carboxyl terminus of all SPRY proteins, and outside of 
this region there is conserved tyrosine residues. SPRY proteins interact with 
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other signalling molecules containing Src-homology-2 (SH2) domains via the 
conserved tyrosine residues region. SPRED (SPRY-related enabled/vasodilator-
stimulated phosphoprotein homology 1 domain containing) proteins are related 
to SPRY proteins structurally and functionally. So far three human, three mouse, 
two Xenopus and one Drosophila SPRED members have been described (DeMille 
et al., 1996, Kato et al., 2003, Sivak et al., 2005). SPRED family members consist 
of the C-terminal cysteine-rich Sprouty-related domain (SPR) shared with SPRY 
proteins, and an N-terminal Enabled/VASP homology 1 domain (EVH1) (Wakioka 
et al., 2001, Kato et al., 2003). 
 
Mammalian SPRY proteins are widely expressed in the developing embryo 
as well as in adult tissues. Some initial studies showed that expression of SPRY 
proteins were regulated by growth factors (Minowada et al., 1999, Tefft et al., 
1999, Chambers and Mason, 2000, Chambers et al., 2000, Su et al., 2002). Large-
scale gene analysis of both human and mouse transcriptomes, showed SPRY2 to 
be ubiquitously expressed, but the other isoforms are more limited to certain 
organs and tissues. For instance, SPRY3 is distributed only in brain and testis 
(Minowada et al., 1999). Given the prototype member of SPRY family is an 
antagonist of RTKs in Drosophila, many reports suggested the involvement of 
SPRY members in various cancer types. SPRY1 and SPRY2 are consistently 
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downregulated at mRNA and protein expression level in more than 90% breast 
cancer patient samples, acting as an inhibitory regulator of Ras/MAPK signalling 
pathway (Lo et al., 2004). In liver cancer, there is evidence for silencing of 
SPRY2 but not SPRY1, but the percentage of patients with low expression of 
SPRY2 is not as great as in breast cancer (Fong et al., 2006). This may due to the 
fact that abnormal RTK signalling plays a pivotal role in breast cancer, and 
emphasises the importance of SPRY in RTK signalling regulation network and 
tumorigenesis. In addition, ectopically expressed SPRY2 in a non-small lung 
cancer cell line and in vivo model reduced cell migration and proliferation via 
inhibition of Ras/MAPK cascade, suggesting a tumour suppressive role in lung 
cancer (Sutterluty et al., 2007). However, there are a few tumour types 
including colon cancer and melanoma, where a controversial role for SPRY is 
suggested. For instance, Spry is shown to be upregulated in global gene 
expression analysis of melanoma cell lines (Bloethner et al., 2005) (Table 1.1). 
Nonetheless, SPRY2 knockdown in melanocytes with wild type BRAF inhibited 
MAPK signalling cascade, but did not affect mutant BRAF containing cells 
(Tsavachidou et al., 2004). Interestingly, human colon adenocarcinoma consists 
of high expression level of SPRY2 compared with normal tissue, and 
overexpression of SPRY2 even exacerbated cell proliferation and invasiveness in 
the xenografts and orthotopic models respectively, suggesting oncogenic 
function of SPRY2 in colon cancer (Holgren et al., 2010). Collectively, these 
evidences suggest the complexity of SPRY2 function in various types of 
carcinogenesis, and emphasise the context dependent nature of SPRY2 action. 
 
Table 1.1 Expression of SPRY2 in a number of cancer types 
Type	  of	  Cancer	   SPRY2	  level	   Reference	  
Breast	  Cancer	   	   (Lo	  et	  al.,	  2004)	  
Colon	  Cancer	   	   (Holgren	  et	  al.,	  2010)	  
Hepatocellular	  Carcinoma	   	   (Fong	  et	  al.,	  2006,	  Lee	  et	  al.,	  2008)	  
Prostate	  Cancer	   	   (McKie	  et	  al.,	  2005)	  
Non-­‐small	  Cell	  Lung	  Cancer	   	   (Sutterluty	  et	  al.,	  2007)	  
Melanoma	   	   (Bloethner	  et	  al.,	  2005)	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1.3 Function of SPRY2 
1.3.1 SPRY2 and growth factor signalling 
The precise mode of SPRY action is difficult to pinpoint, as the functional 
role of the SPRY isoforms in different growth factor pathways varies in a distinct 
cell and tissue dependent manner. Mammalian SPRY proteins are referred to as 
master of modulators of growth factor signalling, and for most RTK signalling 
cascades. For FGF signalling, all of the SPRY isoforms inhibit FGF-induced MAPK 
activation to varying degrees (Lao et al., 2006, Ozaki et al., 2005). Yet, in 
response to EGF stimulation, SPRY2 acts as a positive enhancer and potentiates 
MAPK activation in some cell types (Egan et al., 2002, Fong et al., 2003, Rubin et 
al., 2003). 
Given SPRY2 is the most highly conserved isoforms across vertebrates; 
most research has been heavily focused on SPRY2 in order to elucidate SPRY 
mediated functions. The inhibitory role of SPRY2 was first studied in the FGFR 
signalling cascade. In response to FGF, activation of FGFR recruits downstream 
molecule Shp2, which binds to phosphorylated tyrosines on FRS2. Activation of 
the SOS-Grb2 complex facilitates the activation of membrane-located Ras and 
downstream ERK signalling (Hadari et al., 1998). It is reported that SPRY2 
physically interacts with Grb2 adaptor protein, and results in disruption in the 
formation of adaptor complexes including FRS2 and SOS1, consequently 
inhibiting Ras-Raf-MAPK signalling pathways as shown in the figure 1.3.1 (Lao et 
al., 2006, Martinez et al., 2007). The interaction between Grb2 and SPRY2 was 
attributed to the stronger inhibitory role of SPRY2 compared to its other family 
members SPRY1 and SPRY4, which are due to the weak binding of Grb2-SPRY1 
and SPRY4 only binds to SOS1 and not Grb2 (Ozaki et al., 2005). Interestingly, 
Martinez’s work showed that the mutation at the Grb2 binding sites did not 
affect the inhibitory role of SPRY2 in FGFR signalling, contradicting Lao and 
colleagues’ findings (Lao et al., 2006). The major differences in these two 
studies are the duration of FGFR mediated MAPK activation (transient and stable 
ectopic FGFR transfection) and cell types, hence the inhibitory effect of SPRY2 
in FGF signalling may be considered as temporal and cell context dependent.  
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The impact of SPRY family members in VEGF signalling cascades are often 
implicated in aberrant angiogenesis during carcinogenesis. Upon stimulation of 
VEGFR, PLCγ (phospholipase C gamma) and PKC (protein kinase C) phosphorylate 
Raf1 which in turn activates MAPK signalling molecules in a Ras independent 
manner (Takahashi et al., 2001) (Figure 1.3.1). Consequently, the inhibitory 
action of SPRY is different from other RTK pathways. It is reported that SPRY4 
strongly interacts with Raf1 via its RBD (Raf1 binding domain) and subsequently 
disrupts Raf1 mediated MAPK signalling. Given all SPRY members consists of a 
RBD in their highly conserved C-terminus, it is expected that other SPRY isoforms 
may have similar inhibitory effects in VEGFR signalling pathways.  
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1.3.2 SPRY2 and EGF signalling 
For many years, SPRY2 was generally considered as a Ras-MAPK inhibitor 
in the RTK signalling cascade. However, recent studies challenged the traditional 
view of the SPRY function particularly in EGFR signalling network. The 
controversial view is that SPRY can potentiate MAPK signalling in EGF stimulated 
cells with cell type dependent manner. This is due to the fact that EGFR 
signalling involves a more complex mechanism involved in the balance between 
trafficking and degradation of the receptor. Upon ligand stimulation, EGFR can 
be rapidly degraded in order to control the magnitude of the signalling via 
interaction with the E3 ubiquitin ligase c-Cbl. It is reported that SPRY2 competes 
with EGFR for the c-Cbl binding sites, which in turn prevents the degradation of 
the receptor and enhances EGFR mediated signalling (Haglund et al., 2005). 
Other RTK including FGFR is also degraded by c-Cbl, but SPRY2 does not 
interfere with the interaction between FGFR and c-Cbl. How SPRY2 distinguishes 
between EGFR and FGFR remains to be investigated. Kim and his colleagues 
described that overexpression of SPRY2 delays EGFR trafficking to late 
endosomes, consequently rather potentiating EGFR mediated ERK activation 
(Kim et al., 2007). In summary, SPRY2 exerts tight spatial and temporal 
regulation in order to achieve signalling specificity. 
  
1.4 Regulation of SPRY gene expression and localisation 
Drosophila Spry gene expression is generally controlled by RTK mediated 
transcription. It was first reported that overexpression of Drosophila FGFR 
otholog (Branchless) induced expression of SPRY (Hacohen et al., 1998). In 
mammalian cells, Spry2 and Spry4 expression are induced via activation of EGF, 
FGF and PDGF mediated MAPK function, but FGF and PDGF showed 
downregulation of Spry1 transcription (Gross et al., 2001, Impagnatiello et al., 
2001, Sasaki et al., 2001). Gene array analysis revealed Spry2 gene promoter 
contained FOXO binding elements, and SPRY2 expression level is associated with 
FOXO deletion in endothelial cells (Dejana et al., 2007b).  
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The regulation of SPRY2 protein is achieved by a balance between its 
degradation and synthesis. Growth factors including FGF, EGF and VEGF 
stimulation leads to the induction of Spry gene transcription (Impagnatiello et 
al., 2001, Sasaki et al., 2001, Ozaki et al., 2001), which initiates the negative 
feedback in RTK signalling network. Many reports suggested the phosphorylation 
of serine or tyrosine residues of SPRY2 allows interaction with other regulatory 
molecules, and in turn affects its stability. For instance, upon EGF/FGF 
stimulation, MAPK-interacting kinase 1 (Mnk1) phosphorylates SPRY2 at serine 
112 and 121 residues, which competes with tyrosine phosphorylation at the 
conserved N-terminal. This protects SPRY2 from binding C-cbl, and enhances its 
stability (DaSilva et al., 2006). In addition to C-cbl mediated degradation, a 
yeast two-hybrid screen revealed another E3 ubiquitin ligase interaction partner 
SIAH2, which binds to SPRY2 regardless of RTK mediated tyrosine 
phosphorylation (Nadeau et al., 2007). All together, SPRY2 as a key regulator of 
RTK is tightly regulated in a temporal manner both in transcription and post-
translational level.  
 
1.5 SPRY2 in prostate carcinogenesis  
As mentioned before, loss of SPRY2 appears to be a common event in 
many tumour types, particularly in prostate cancer. First report from Kwabi-
Addo showed an involvement of SPRY family member SPRY1 in prostate 
carcinogenesis (Kwabi-Addo et al., 2004). The prostate cancer TMA (tissue 
microarray) analysis revealed over a third of patients showed SPRY1 
downregulation compared to normal tissue. However, the result was debatable, 
as some prostate tumours showed upregulation of SPRY1. Also it is reported that 
SPRY2 expression is controlled by genomic methylation, particularly in prostate 
cancer. Patient TMA analysis showed that high-grade tumours (gleason score 3-5) 
had less SPRY2 mRNA level compared to benign prostatic hyperplasia (BPH), 
indicating a potential tumour suppressor role of SPRY in prostate carcinogenesis 
(McKie et al., 2005). There is evidence of loss of heterozygosity (LOH), but with 
lower incidence than epigenetic silencing. In addition, recent cBio Cancer 
Genomic Portal analysis showed 26% of cases (n=103) with down-regulation of 
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SPRY2, with no case of mutation or copy number changes in Spry2 gene. In 
metastatic PC cases (n=37), there were 14 cases that reduced SPRY2 expression. 
Furthermore, patients with low level of SPRY2 expression showed significantly 
poorer survival outcome compared with unaltered SPRY2 expression level (Figure 
1.5.1). In summary, loss of SPRY2 is an important event in prostate 
carcinogenesis. However, at what stage SPRY2 loss occurs and what its 
functional impact is remain to be elucidated. 
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1.6 Aims of the project 
The aim of this study is to investigate the impact of SPRY2 loss in prostate 
carcinogenesis, particularly the controversial mechanism involved in the 
crosstalk between SPRY2, EGFR and PTEN/PI3K/AKT signalling networks in 
advanced prostate cancer including the use of preclinical models. The functional 
impact of SPRY2 loss is described in prostate cancer cell lines and in vivo in a 
preclinical mouse model. The involvement of SPRY2 reduction in RTK signalling 
pathway was investigated including EGFR/HER2 trafficking and downstream 
signalling cascades. Given the important function of SPRY2 loss in prostate 
cancer, we assessed targeted chemotherapeutic strategies in a Spry+/- Pten+/fl 
preclinical model. Finally the potential interaction partners of SPRY2 in prostate 
cancer cell lines are examined using SILAC proteomic technology 
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Chapter 2. Materials and Methods 
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2. Materials and Methods 
2.1 Materials 
All general laboratory reagents used in this study are listed in Table 2.1 
below. 
Table 2.1 General reagents 
Reagent Source 
Ampicillin Sigma 
BSA (bovine serum albumin) Sigma 
DAPI (4',6-diamidino-2-phenylindole) Vector 
DMEM (Dulbecco's Modified Eagle's 
Medium) GIBCO 
DMSO (dimethyl sulfoxide) Fisher Scientific 
ECL (enhanced chemiluminescence) GE healthcare 
Ethanol Sigma 
F12 GIBCO 
FBS (fetal bovine serum) PAA 
kanamycin Sigma 
L-glutamine GIBCO 
Lipofectamine 2000 Invitrogen 
Matrigel Invitrogen 
Methanol Sigma 
MOPS SDS running buffer (20x) Invitrogen 
NaCl Sigma 
Nitrolcellulose membranes Fisher Scientific 
Penicillin Streptomycin GIBCO 
PFA (paraformaldehyde) Science Services 
Phosphatase inhibitors cocktail Thermo Scientific 
Protease inhibitors cocktail Thermo Scientific 
RPMI-1640 GIBCO 
SimplyBlue Safestain Invitrogen 
Tris-HCl Sigma 
Triton X-100 Sigma 
Trypsin GIBCO 
Tween-20 Sigma 
β-Mercaptoethanol Sigma 
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All buffers and solutions used in the study are listed in Table 2.2. 
Table 2.2 Solutions and buffers 
Solution Composition 
Phosphate Buffered Saline (PBS) 170 mM NaCl 
 3.3 mM KCl 
 1.8 mM Na2HPO4 
 10.6 mM KH2PO4 
  PH 7.4 
Tris-buffered saline - Tween (TBST) 25 mM Tris - HCl pH 7.4 
 137 mM NaCl 
 5 mM KCl 
  0.1% Tween - 20 
Immunoblotting buffer 192 mM glycine 
 25 mM Tris 
  20% methanol 
Lysis buffer 50 mM Tris - HCl pH7.5 
 150 mM NaCl 
 1% Triton 
  1 mM EDTA 
Fixing solution 4% PFA 
  96% PBS 
Blocking buffer (Immunoblotting) 5% w/v milk powder in 
TBS-T 
Blocking buffer 
(immunofluorescence) 10% FBS 
 1% w/v BSA 
  90% PBS 
Permeabilizing solution 
(immunofluorescence) 0.1% Triton X-100 in PBS 
Lysogeny broth (LB) 1% Bacto-tryptone 
 86 mM NaCl 
  0.5% yeast extract 
LB agar 1.5% agar 
Tris-EDTA (TE) 10 mM Tris-HCl pH 8.0 
  1 mM EDTA 
3x SDS-PAGE sample buffer 125 mM Tris pH 6.8 
 4% SDS 
 15% β-Mercaptoethanol 
 15% glycerol 
  0.01% bromophenol blue 
Citrate buffer PH6 10 mM sodium citrate 
  0.05% Tween 20 
Tris-buffered Saline (TBS) 25 mM Tris - HCl pH 7.4 
 137 mM NaCl 
  5 mM KCl 
   36 
 
2.2 Methods 
2.2.1 Cells and Growth Condition 
Human prostate cancer cell lines DU145, PC3, LNCaP and CWR-22 were 
authenticated by LCG standards and purchased from ATCC. These cells were 
grown in RPMI (Gibco) containing 10% fetal bovine serum (FBS) and 2mM L-
Glutamine (GIBCO) at sub-confluent conditions. Cells were maintained as 
described previously (Masters and Stacey, 2007). Briefly, cells were grown in a 
humidified incubator at 37°C in 5% CO2 and passaged every 3-4 days. Medium 
was aspirated and cells were washed with PBS once, followed by incubation with 
Trypsin (Invitrogen). Cells were collected and counted with CASY® cell counter 
(Innovatis) and seeded for maintenance. 
For long-term storage cell lines were cryo-frozen. Cells were trypsinised 
and resuspended in 50% FBS, 40% full medium and 10% DMSO, then froze in 
cryotubes (Nunc) at -80°C overnight and stored in liquid nitrogen. 
  
2.2.2 Cell Proliferation Assay 
Cells were seeded at a concentration of 5 x 103cells/well in 100 µl culture 
medium into microplates (tissue culture grade, 96-wells, flat bottom) (Becton 
Dickinson). After various treatments for 48 h at 37°C and 5% CO2 condition, 10µl 
Cell Proliferation Reagent WST-1 (Roche) was added and incubated for 30 mins. 
The absorbance of the samples against a background control as blank was 
measured using a microplate (ELISA) reader. The wavelength for measuring the 
absorbance was 450nm and the reference wavelength was set at 650nm. 
2.2.3 Matrigel Invasion Assay 
For the invasion assay, the 24-well configuration of the BioCoat™ 
Matrigel™ Invasion chambers (BD Sciences) was used. The matrigel was 
rehydrated with warm serum free medium for 2h in a humidified tissue culture 
incubator. After incubation, 40,000 cells/well were seeded in triplicate and 
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allowed to invade through transwell chambers with 8 mm pore membranes 
coated with matrigel for 8 h with 10% serum or 20 ng/ml EGF (Invitrogen) as 
chemo-attractant. The chemo-attractant was added in the wells of a companion 
plate. After incubation, the non-invading cells were removed from the upper 
surface of the membrane using cotton buds. Cells that had invaded to the lower 
surface of the membrane were fixed in 100% methanol and the membrane was 
mounted onto slides. Invaded cells were stained with DAPI and visualised under 
microscope (Nikon). 
2.2.4 Receptor Internalisation Assay 
EGFR internalisation assays were performed after overnight serum 
starvation followed by EGF (Invitrogen) treatment (20 ng/ml) as described 
previously (Sarto et al., 2007). Cells were coated with NHS-S-S-biotin (Sigma) 
before EGF treatment for 30 mins at 4°C with rocking, then cells were washed 2 
times with cold PBS. The cell surface biotin was reduced with cell impermeable 
MesNa (sodium 2-mercapto-ethanesulfonate) (Sigma) for 1 h with rocking at 4°C. 
The reaction was stopped with reducing agent iodoacetamide (Sigma). Cells 
were washed with PBS 2 times, and WCL (whole cell lysate) were collected for 
either ELISA or IP (Immunoprecipitation) experiments. For ELISA detection, 96 
well plates were coated with EGFR antibody overnight and washed with PBST (5% 
BSA). Internalisation assays were performed in the presence of 0.6 mM of 
primaquine (Sigma). For IP, the internalisation was performed and whole cell 
lysates were used to IP the biotin labelled EGFR with Dynabeads® (Invitrogen) or 
NeutrAvidin (Thermo Scientific) instead of ELISA plates. Dynabeads® were 
incubated with EGFR antibody (BD bioscience) for 1h at 4°C, and the beads were 
washed with lysis buffer 3 times before added to the WCL for IP. Proteins bound 
to the beads were eluted by boiling, and western blot analysis was performed.  
2.2.5 Immunoblotting 
Cells were lysed with lysis buffer containing Halt protease inhibitor 
cocktail (Thermo Scientific) and Halt phosphatase inhibitor cocktail (Thermo 
Scientific) as described by the manufactures instruction. Briefly, the whole cell 
lysate were centrifuged for 15 mins at 13200 rpm, and the supernatant was 
collected for measurement of protein concentration. Bio-RAD Protein Assay (Bio-
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RAD) and spectrophotometer (595 nm) was used for determining protein 
concentration. All the protein samples were adjusted to be at equal 
concentration with lysis buffer. Subsequently the samples were boiled in 3x 
sample buffer for 10 min at 100°C and loaded in NuPAGE 4-12% Bis-Tris Gel 
(Invitrogen). The gels were electrophoresed in XCell SureLock Mini-Cell tank 
(Invitrogen) at 120mA and 200V in 1x MOPS SDS running buffer (Invitrogen).  
The separated proteins were transferred from the gel to nitrocellulose 
membrane using semi-dry western transfer in 1x transfer buffer. Each gel was 
transferred at 20 V and 200 mA for 1h. The membranes were blocked in 5% milk 
(Marvel)/TBST for 60 mins incubated with primary antibodies solution overnight 
at 4°C. After washing with 3x TBS-T for 5 mins, secondary antibodies were 
added in the blocking solution for 1h at room temperature. The antibodies used 
in this study are listed in Table 2.4. The proteins on the membrane were 
visualised by ECL detection kit (GE Healthcare). 
2.2.6 Transfection 
For generation of stable SPRY2 knock down cell lines, a 19mer sprouty2 
target sequenc (5’-AACACCAATGAGTACACAGAG-3’) (Qiagen) was used, and non-
silencing control sequence was obtained from Qiagen. Plasmid pTER+ were used 
to insert the sequence of interest, and stably expressed in DU145 and PC3 cell 
lines. The stable SPRY2 KD cell lines were generated by Dr Rachana Patel. For 
transient SPRY2 siRNA transfection, two different siRNA sequences were 
purchased from Dharmacon, and PTEN siRNA was obtained from Cell Signalling. 
Transfection was carried out with Amaxa Cell Line Nucleofactor Kit (Lonza) as 
manufactors instruction.  
For IP and IF, plasmids were transfected into cells with Lipofectamine™ 
2000 (Invitrogen) following the manufacturer’s instructions. For 150 mm plate, 3 
µg of appropriate DNA plasmids were mixed with 1 ml serum free medium and 
20µl Lipofectamine™ 2000, and incubated at room temperature for 20 mins to 
allow DNA-Lipofectamine™ 2000 complexes to form. After incubation, the 
mixture was added to the cells drop wise. Cells were incubated in humidified 
tissue culture incubator until ready to assay (24-48 h post transfection). 
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2.2.7 Immunofluorescence (IF)  
Cells were transfected with GFP-EEA1 vector (Addgene) for 24 h and fixed 
in 4% paraformaldehyde for 15 mins. Cells were permeabilised with 0.1% Triton 
X-100 (Sigma). Non-specific binding was blocked with a mixture of 10% FBS, 1% 
BSA and PBS. Then the blocking solution was removed and cells were incubated 
with appropriate primary antibodies for 1h at room temperature. Primary 
antibodies were diluted in 10% FBS, 1% BSA and PBS. Alexa Fluor® 555 and 488 
(Invitrogen) was used as secondary antibody, and the nucleus was stained with 
DAPI. Simultaneous dual fluorescence acquisitions were performed using 
confocal microscope (Nikon) with 488 and 568 nm laser lines to visualise GFP and 
Texas red dyes using 60x oil immersion (scale bar 20µm).  
2.2.8 SILAC (stable isotope labelling with amino acids in cell culture) labelling 
Cells were grown in the medium containing appropriate stable isotopic 
amino acids reagents listed below for at least 5 passages. The whole cell lysates 
were collected and tested for incorporation.  When the incorporation rate 
reached above 90%, cells were used for IP experiments.  
Table 2.3 Stable isotopic amino acids used in SILAC media 
Stable 
isotopic 
amino acids 
Concentration 
in RPMI 
Mass 
difference 
Source Combination 
L-lysine 2HCL 100mg/L 0Da Sigma Light 
L-Arginine HCl 100mg/L 0Da Sigma Light 
L-Lysine 2HCl 
(4,4,5,5-D4) 
100mg/L 4Da Cambridge 
Isotope 
Medium 
L-Arginine 
(13C6) 
50mg/L 6Da Cambridge 
Isotope 
Medium 
L-Lysine 2HCl 
(13C6, 15N2) 
100mg/L 8Da Cambridge 
Isotope 
Heavy 
L-Arginine HCl 
(13C6, 15N4) 
50mg/L 10Da Cambridge 
Isotope 
Heavy 
 
2.2.9 Immunoprecipitation (IP) 
Prior to harvesting the cells, they were transfected with GFP (Addgene) or 
GFP tagged SPRY2 plasmids for 48 h. GFP tagged SPRY2 plasmid was constructed 
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with inserting SPRY2 sequence into GFP plasmid. Cells were stimulated with 100 
ng/ml EGF after 24 h starvation. Cells were lysed in lysis buffer and the lysate 
was cleared by centrifugation at 13000 rpm for 15 min at 4°C. The whole cell 
lysates were incubated with GFP-Trap®_A beads (Chromotek) at 4°C for 1h with 
rotation. The beads were washed 3 times with lysis buffer and then boiled at 
100°C in 1% SDS to elute IP proteins bound to the beads. 
2.2.10 Animals 
All animal experiments were carried out under the UK Home Office 
guidelines (project licence 60/3947, and personal licenced 12870). Mice were of 
a mixed background and littermates were used as control mice. 
Nkx 3.1-Cre (Hsieh et al., 2010) mice were crossed to those harbouring 
Spry2+/- (Shim et al., 2005) and Ptenfl/+ (Lesche et al., 2002).  The mice were 
genotyped by PCR by TransnetyxTM (Shim et al., 2005, Lesche et al., 2002, 
Andrechek et al., 2000). Prostates were dissected out and placed in formalin for 
overnight fixation before paraffin embedding. 
PI 103 treatment was commenced when the prostate tumour was palpable 
in the mouse model (10-11 months). PI 103 was injected daily 50 mg/kg intra-
peritioneal (ip) for 4 weeks. Prostate tissues were collected and fixed in 
formalin or frozen in liquid nitrogen for western analysis.  
2.2.11 Immunohistochemistry 
Tissue samples were formalin-fixed, paraffin-embedded, and stained for 
at least 3 samples from 3 different mice. The tissue sections were prepared in 
the histology services. For Ki67 staining, Ki67 antibody (Vector Labs) was used at 
1/100 dilution, and antigen unmasking was performed in citrate buffer (pH 6) 
and incubated for 50 mins at 99oC in a water bath. For p-AKT (ser473) (Cell 
Signaling, 1/50 dilution) and pERK1/2 (Cell Signaling, 1:100 dilution), citrate 
buffer or Tris/EDTA buffer (pH8) and microwave antigen retrieval method was 
used. The antibodies are listed in the Table 2.4. 
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2.2.12 Tissue microarray analysis of human prostate cancer 
With ethical approval (MREC 01/0/36), formalin-fixed, paraffin-embedded 
(FFPE) sections from 239 patients were studied. These consisted of 209 primary 
prostate carcinomas (PC) and 30 benign prostatic hyperplasia (BPH) samples. 
Three 0.6mm cores of prostate cancer tissue from each case were identified by 
pathologists and removed from representative areas of the FFPE blocks. All 
cancer samples had been taken from prostate cancer patients at the time of 
trans-urethral resection of the prostate (TURP). These samples consisted of 
Gleason 3 (n=123), 4 (n=49) to 5 (n=37) cancers, as determined independently by 
two consultant pathologists (MS and RJB). These samples were processed by 
immunohistochemistry. Survival analysis was performed using Kaplan Meier plot 
and log rank test. 
2.2.13 Statistics 
All the statistical analysis was performed using Prism 5 software, and all 
graphs were generated using Microsoft Excel software. The error bars were 
calculated and represented in terms of mean ± SD. 
 
Table 2.4 List of antibodies used in this study 
Antigen Supplier Dilution 
Actin Sigma; A4700 1:1000 
AKT Cell Signaling; 9272 1:1000 
ATF2 Cell Signaling; 9226 1:1000 
BRaf Cell Signaling; 9433 1:1000 
CKB Abcam; ab38212 1:1000 
Clathrin Cell Signaling; 4796 1:1000 
EGFR Cell Signaling (western) 1:1000 
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Santa Cruz; sc103 (IHC) 
BD Bioscience (IP and IF) 
1:100 
1:!00 
ERK1/2 Cell Signaling; 9102 1:1000 
GAPDH Sigma; G9295 1:12000 
GFP Cell Signaling; 2956 1:1000 
HER2 
Cell Signaling; 8339 
(western) 
Cell signalling (IHC) 
1:1000 
1:100 
HER3 Cell Signaling; 8339 1:1000 
p-AKT 
Cell Signaling; 4060 
(western) 
Cell signalling (IHC) 
1:1000 
1:100 
p-ATF2 Cell Signaling; 9221 1:1000 
p-EGFR Cell Signaling; 9922 1:1000 
p-ERK1/2 
Cell Signaling; 9101 
(western) 
Cell signaling (IHC) 
1:1000 
1:100 
p-HER2 Cell Signaling; 8339 1:1000 
p-HER3 Cell Signaling; 8339 1:1000 
p-p38 Cell Signaling; 9790 1:1000 
P38 Cell Signaling; 9790 1:1000 
PKM2 Cell Signaling; 3198 1:1000 
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PP2A Cell Signaling; 2259 1:1000 
PTEN 
Cell Signaling; 9188 
(western) 
Cell Signaling (IHC) 
1:1000 
1:50 
SPRY2 
Abcam; ab50317 (IHC) 
Sigma; s1444 (western) 
1:50 
1:1000 
Tubulin Sigma; T6557 1:2000 
FLAG Sigma; F3165 1:100 
Anti-rabbit IgG, HRP-
linked Antibody  
Cell Sigmaling; 7074 1:5000 
Anti-mouse IgG, HRP-
linked Antibody 
Cell Signaling; 7076 1:5000 
 
Table 2.5 List of inhibitors used in this study 
Inhibitors Suppliers Dilutions 
Gefitinib LC Laboratories; G4408 15 μM 
Lapatinib LC Laboratories; L4804 10 μM 
SB203580 Sigma; s8307 10 μM 
PI103 Tocris Bioscience; 2930 50 mg/kg 
LY294002 Sigma; L9908 10 μM 
Dynasore Sigma; D7693 5 μM 
PD098059 Sigma; p215 10 μM 
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Chapter 3. Functional contribution of SPRY2 in 
human PC cells and a preclinical mouse model 
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3 Functional contribution of SPRY2 in PC cell line and 
preclinical mouse model 
In prostate cancer, work from our laboratory has previously showed that 
SPRY2, one of mammalian SPRY orthologues (SPRY 1-4), is epigenetically 
silenced in almost 70% of primary prostate cancer (McKie et al., 2005). SPRY2 
physically interacts with several adaptor/regulator proteins downstream of 
RTKs, including PP2A, Grb2, Braf, Shp2, c-Cbl and GAP1 (Danese et al., 2007). 
The large number of binding partners for SPRY2 is consistent with its crucial yet 
complicated role in RTK signalling. Indeed, whether SPRY2 functions as a 
positive or negative regulator in EGFR signalling network remains an important 
question. In addition to its well-reported function as an inhibitor of 
RAS/RAF/MEK signalling cascade (Bordoni et al., 2007), Edwin and his colleagues 
reported that SPRY2 exerts its inhibitory role in PI3K/AKT signalling pathway 
through PTEN, by enhancing its activation and stability (Edwin et al., 2006). 
PTEN is among the most commonly mutated genes in human cancer, including 
prostate cancer. Progressive inactivation or loss of PTEN appears to be involved 
in development of invasive and metastatic PC. Transgenic mice with PTEN 
heterozygous deletion targeted to the prostate develop high-grade PIN, which 
fails to progress into invasive phenotype (Mellinghoff et al., 2004). Furthermore, 
complete loss of PTEN is thought to be a late event and can be considered a 
critical landmark for progression to aggressive and invasive disease. Indeed, the 
Pten null murine prostate cancer model developed invasive adenocarcinoma 
(Song et al., 2011). This is consistent with the cBio portal data, which revealed 
~24% (25/104) of PC retains PTEN expression albeit at low levels and only ~7% 
(7/104) of PC showed evidence of homozygous Pten deletion (cBio Cancer 
Genomics Portal) (Taylor et al., 2010). It is worth noting that as many as 50% 
(17/37) of metastatic tumours harboured biallelic Pten loss. 
To date, functional studies of SPRY2 have studied effects of transiently or 
stably over-expressed SPRY2 in in vitro cell models (Kawakami et al., 2009, 
Rubin et al., 2003). As SPRY2 expression tends to be suppressed in cancer, we 
set out to investigate the significance of SPRY2 loss using human prostate cancer 
cell models with knocked down SPRY2 expression and a preclinical mouse model. 
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3.1 Analysis of SPRY2 expression and effect of SPRY2 loss in 
prostate cancer cell lines 
In order to understand the effect of SPRY2 in prostate cancer progression, 
the expression of SPRY2 was examined in various prostate cancer cell lines, 
including PC3, PC3M, LNCAP, DU145, CWR22 and PNT-2A. The classic prostate 
cancer cell lines including PC3 and DU145 were obtained from a patient with 
metastatic PC, and PC3 cell line is generally considered having more invasive 
ability compared to DU145. DU145 is derived from a distant metastatic organ 
(brain) in a PC patient. Among these cancer cell lines, except LNCAP cells 
expression of SPRY2 is detected by western blot analysis (Figure 3.1.1). 
Considering the important role of PTEN in the function of SPRY2, PC3 and DU145 
cell lines were selected to further study the effect of SPRY2 loss, since they 
have PTEN null and positive background respectively. 
 
 
Stable knockdown of SPRY2 clones of prostate cancer cell line DU145 
(CL13 and CL61) and PC3 (CL1 and CL10) along with non-silencing control (Nsi) 
cells were generated. Western blot analysis confirmed reduction of SPRY2 
expression in knockdown clones (Figure 3.1.2). Due to the difference in the 
shRNA sequence, the knockdown effect was expected to be different; 
consequently the impact of the two shRNA in SPRY2 KD clones may vary. The 
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effect of SPRY2 KD in DU145 and PC3 were examined in response to EGF 
stimulation. Upon the ligand binding, DU145 SPRY2 KD clones 13 and 61 showed 
significantly more EGF mediated proliferation compared to the Nsi control. 
However, PC3 cells did not show any difference in cell growth between SPRY2 KD 
clones and control cells (Figure 3.1.2). Such difference may be attributed to the 
PTEN status in these cells. It is reported that presence of PTEN is essential for 
SPRY2 to act as an inhibitory regulator in RTK signalling cascades, particularly in 
cell proliferation (Edwin et al., 2006). In addition, matrigel plug was used to test 
the invasiveness of SPRY2 KD cells. The PTEN positive DU145 cells with reduced 
SPRY2 expression showed over 40% more cells invading through the matrigel 
towards to the chemoattractant EGF when compared to Nsi control cells. The 
number of invading SPRY2 KD cells were visualised with DAPI staining and were 
more than 2 fold higher than that observed for Nsi control cells. Interestingly, 
loss of SPRY2 in PC3 cells decreased the invasiveness in response to EGF (Figure 
3.1.3). We reasoned the difference in proliferation and invasiveness in PC3 and 
DU145 with loss of SPRY2 may be attributed to the level of PTEN expression.  
In order to investigate the functional effects of PTEN in relation to SPRY2 
expression status, we used siRNA to transiently KD PTEN in DU145 Nsi and SPRY2 
KD cells. Western blot analysis showed the reduction of PTEN expression with 
the siRNA transfection but not with the control scramble siRNA treated cells 
(Figure 3.1.4). Consistent with my hypothesis, the concomitant loss of SPRY2 and 
PTEN expression in DU145 cells led to one-fifth reduction in invasion, and there 
was no alteration observed in cell growth. Furthermore, there were increases 
both in cell growth and invasion in Du Nsi cells with PTEN siRNA tranfection 
(Figure 3.1.4). Reduction in PTEN level may release the inhibition of PI3K/AKT 
signalling pathways, which leads to the increase in proliferation and invasion in 
Nsi cells. Overall, loss of SPRY2 cooperates with EGF stimulation, and enhances 
cell proliferation and invasion in PTEN-dependent manner. 
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3.2 Loss of SPRY2 enhances the activation of EGFR signalling 
pathways upon EGF stimulation 
Downstream signalling following EGF stimulation in SPRY2 KD DU145 cells 
was examined using the Human Phospho-Kinase Array. Cells were serum starved 
overnight and stimulated with EGF for 15 minutes. Among the 46 phospho-kinase 
profile, PI3K/AKT and MAPK were key pathways activated upon EGF stimulation. 
Interestingly, we only observed a difference (20%) in AKT phosphorylation at 
serine 473, but not threonine 308. Activation of PI3K/AKT can lead to elevation 
of JNK phosphorylation, which contributes to prostate tumour cell proliferation 
and angiogenesis (Slack et al., 2005). Downstream signalling components of 
PI3K/AKT and MAPK such as JNK and c-Jun also showed higher level of 
phosphorylation in SPRY2 KD cells. Since DU145 cells have amplification of Ras, 
and an inhibitory effect of SPRY2 in Ras-MEK-ERK, both MEK1/2 and its 
downstream ERK1/2 are activated. We also observed enhanced activation of the 
stress MAP kinase p38 in SPRY2 KD cells by EGF (Figure 3.2.1). For p-P38 signal, 
the membrane was exposed slightly longer to detect the difference, it may be 
due to the sensitivity of p-P38 antibody in the assay kit or the amount of 
phosphorylated form of P38 is relatively less compared to other proteins (Figure 
3.2.2). Some of the above findings were confirmed in Western blot following 15 
and 30 minutes of EGF stimulation. As we expected, the PTEN null PC3 cells 
showed less activated level of p-AKT in SPRY2 KD cells compared to Nsi control 
cells (Figure 3.2.3). Thus there were no significant difference in increase of 
proliferation and invasiveness in SPRY2 KD PC3 cells compared to the Nsi control 
cells, which were observed in Chapter 3.1. Together, loss of SPRY2 activates 
PI3K/AKT signalling cascade, which is a key component for the EGF driven cell 
growth and invasion. 
   52 
 
 
 
 
 
 
 
 
 
   53 
 
 
 
 
 
 
 
 
 
 
   54 
 
 
 
  
   55 
3.3 Loss of SPRY2 and PTEN in a preclinical mouse model 
The preclinical mouse model for prostate cancer is often studied using a 
conditional gene knockout (KO) method, which allows the functional analysis of 
the gene of interest. One of the common systems is the Cre loxP recombination 
system, which gives tissue specific gene alterations (Nagy, 2000). The technology 
works as follows: loxP sequence flanks the specific gene, and upon Cre 
recombinase expression the target gene is deleted through recombination 
between loxP sites. For the prostate, the organ specific deletion is often 
achieved with the Pb-Cre4 or Nkx3.1-Cre mediated strategies (Trotman et al., 
2003a). Nkx Cre driven recombination occurs in the prostate epithelium, and 
also affects other organs during development (Thomsen et al., 2008, Zhang et 
al., 2008). Given the critical tumour suppressor role of PTEN, there are several 
reports on PTEN deletion in PC mouse model. Germline deletion of one Pten 
allele developed PIN and high grade PIN, but no adenocarcinoma or invasive 
prostate cancer was observed (Podsypanina et al., 1999, Di Cristofano et al., 
1998). In addition more aggressive adenocarcinoma of prostate was observed 
when combinations of other oncogenic genes were engineered to cooperate with 
PTEN including c-Myc, p53, TMPRSS-ERG fusion (Carver et al., 2009, King et al., 
2009b, Chen et al., 2005, Kim et al., 2009).  
Considering the in vitro data shown in Chapter 3.1 and published human 
genomic data, the Spry2 and Pten heterozygous mouse model was generated to 
investigate the effect of SPRY2 and PTEN in prostate carcinogenesis. Nkx Ptenfl/+ 
Spry2+/- mouse were generated and the prostate tissue was harvested from mice 
around 10-12 months old. The H&E staining showed Ptenfl/+ developed PIN lesions 
in the prostate gland. The epithelial cells contained enlarged nuclei, and part of 
the epithelium showed irregular appearance and abnormal growth next to the 
normal cells (Figure 3.3.1). In contrast, loss of SPRY2 and PTEN resulted in 
aggressive prostate tumour, the glandular structure is no longer visible, and 
cancer cells infiltrated into surrounding areas (Figure 3.3.1). As expected, there 
are more Ki67 staining positive cells in the prostate epithelium of Ptenfl/+ Spry2+/- 
mice compared to that in Ptenfl/+ mice, indicating uncontrolled proliferation in 
the adenocarcinoma. Evidence suggested that loss of PTEN leads to the 
activation of PI3K/AKt signalling, with both Ptenfl/+ Spry2+/- and Ptenfl/+ showing 
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enhanced AKT activation, but the former with more aggressive phenotype 
showed relatively higher levels of pAKT with predominantly plasma membrane 
staining. In addition to PI3K/AKT signalling, pERK1/2 activation was also 
assessed, immunohistochemistry (IHC) results suggested enhanced pERK1/2 
expression is restricted to only focal areas within the prostate (Figure 3.3.2). 
Altogether, concomitant loss of tumour suppressor gene Pten and Spry2 leads to 
activation of PI3K/AKT and drives aggressive prostate carcinogenesis in vivo. 
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3.4 Summary and discussion 
SPRY2 was reported to be downregulated in several cancer types including 
PC. The function of SPRY2 was examined using human prostate cancer. The 
results suggested SPRY2 acts as a negative regulator, and reduced SPRY2 
expression enhanced cell proliferation and invasiveness in response to EGF 
stimulation. These observations require the presence of PTEN, which is 
consistent with Edwin’s report proposing PTEN’s essential role for  inhibitory 
effect of SPRY2 (Edwin et al., 2006). Human phospho-kinase array analysis 
revealed that loss of SPRY2 activates PI3K/AKT signalling cascades, which may 
be responsible for the aggressive phenotype observed in SPRY2 KD cells. Mutual 
exclusivity test using cBio Cancer Genomic Portal showed the odd ratio was 7.58 
(p=0.002095), which is indicating a strong tendency toward co-occurrence. The 
murine model was used to examine whether PTEN and SPRY2 loss cooperate in 
prostate carcinogenesis. Nkx Ptenfl/+ Spry2+/- mouse model indeed progressed to 
an aggressive PC with lymph node metastasis by 10-12 months of age. The 
prostate tumours exhibited hyperactivation of p-AKT rather than MAPK 
activation. It is interesting that unlike lung cancer, there is very rare 
mutation/amplication of Ras/Raf in PC, which are often attributed to the 
abnormal activation of MAPK signalling. Concomitant low levels of two tumour 
suppressors SPRY2 and PTEN favour the activation of PI3K/AKT signalling 
cascades, which override normal checkpoints to result in tumour formation. 
Collectively, these results allow us to investigate PI3K/AKT as a potential target, 
and the mechanism of SPRY2 and PTEN cooperation in RTK needs to be 
elucidated. 
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4 Modulation of EGFR and ErbB2 trafficking and signalling 
following SPRY2 KD  
Prostate organogenesis and tumorigenesis are both critically dependent on 
androgen receptor (AR) signalling (Potente et al., 2007). Androgen depletion 
therapy is often used but will eventually result in progression to castrate 
resistant disease. Recent studies proposed that abnormal activity of receptor 
tyrosine kinases (RTK), particularly deregulated EGFR signalling is attributed to 
the acquisition of an androgen independent state in prostate cancer (Traish and 
Morgentaler, 2009). Despite an important role for the EGFR system, targeted 
therapies against the EGFR system in prostate cancer have been disappointing 
(Trotman et al., 2003a). Such discrepancies may be explained by complex 
regulatory mechanisms for the EGFR system and its downstream signalling 
cascade. 
EGFR is a member of the ErbB family, which also consists of HER-2, 3 and 
4. Epidermal growth factor (EGF) binding at cell surface induces receptor 
dimerization, activation of its tyrosine kinase domain and subsequent 
downstream signalling events, including both phosphatidylinositol 3-kinase 
(PI3K)/AKT and Ras/Raf/MEK pathways, which are pivotal in controlling 
proliferation and survival (Baluk et al., 2007, Dejana et al., 2007a). 
Concurrently, upon EGF binding, the receptor-ligand complexes internalise into 
endosomal compartments. Previously, the primary role of endocytosis was 
thought to terminate activation of RTKs. The attenuation of the receptors by 
endosomal degradation was even proposed to have a tumour suppressor role 
(Zhang et al., 1997, Kim et al., 2002a). However, several studies revealed that 
RTKs continuously recruit signalling molecules at the intracellular 
compartments, maintaining and amplifying its signalling outcome. EGFR 
signalling forms a complex signalling network with positive and negative 
regulators. SPRY protein was first described by Hacohen and colleagues 
(Hacohen et al., 1998), as an antagonist of fibroblast growth factor (FGF) 
signalling in Drosophila. Sprouty (SPRY) proteins are commonly deregulated in 
human cancers including melanoma and colon cancer (Weber et al., 2007, 
Woodfin et al., 2007). More recently, clathrin-mediated endocytosis upon EGFR 
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activation appeared to be particularly important for the activation of AKT and 
MAPK (Kim et al., 2002b). Zwang and Yarden (Zwang and Yarden, 2006) also 
proposed that the fate of EGFR was determined by the status of the stress kinase 
p38 MAPK, the activation of which allowed tumour cells to evade 
chemotherapeutic agents.  
4.1 Loss of SPRY2 alters EGFR localisation and internalisation  
Upon ligand binding, EGFR is involved in a series of trafficking events, 
which ultimately regulate its signal amplification and propagation. To determine 
how SPRY2 KD promotes EGF driven growth and invasion described in Chapter 3, 
we investigated the intracellular distribution of EGFR using fluorescence 
microscopy. Both Nsi control and SPRY2 KD DU145 cells were transiently 
transfected with GFP-tagged EEA1 plasmid transiently, which labels the 
endosomal compartment within the cells. In unstimulated cells, EGFR was 
predominantly localised to the cell surface. Following EGF stimulation, EGFR 
began to co-localise with EEA1 positive early endosomes in both Nsi control and 
SPRY2 KD cells at 20 and 30 minutes. Importantly, at 30 minutes following 
stimulation with EGF, SPRY2 KD DU145 cells showed enhanced and sustained 
localisation of EGFR at the early endosomes compared to the Nsi control cells 
(Figure 4.1.1). 
To characterise the molecular basis of EGFR trafficking to the early 
endosomes, the internalisation kinetics of EGFR in SPRY2 KD DU145 cells was 
studied. Cell surface proteins were labelled with NHS-S-S-biotin, and then 
stimulation with EGF allows various surface protein to endocytose including 
EGFR at the indicated time. In order to capture internalised and biotin labelled 
EGFR, surface biotin was reduced with cell impermeable reducing agent. IP was 
carried out with EGFR antibody linked dynabeads after reducing surface biotin. 
This allowed us to pull down EGFR labelled with biotin at surface and trafficked 
into the endosomal compartments. As a control, surface biotin was not removed 
from the sample at 0 minutes. For subsequent time points only biotin-labelled 
EGFR (internalised EGFR) were detected with HRP-avidin among pulled down 
mixture of labelled and unlabelled EGFR pool. Western blot analysis showed 
similar total EGFR level in Nsi and SPRY2 KD cells. However, increased level of 
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intracellular EGFR in SPRY2 KD DU145 cells following EGF treatment for 15, 30 
and 60 minutes in the presence of primaquine (a receptor recycling inhibitor). 
Increased internalisation and accumulation of EGFR in SPRY2 KD cells was also 
studied using the NHS-S-S-biotin internalisation assay in an ELISA format. 96-well 
plates were coated with EGFR antibody and incubated with whole cell lysates, 
which were collected after internalisation assay. There was significantly more 
(20%) intracellular EGFR detected in SPRY2 KD cells compared with Nsi control 
cells at 30 minutes of EGF stimulation (Figure 4.1.2).  
EGFR trafficking employs mainly clathrin-dependent endocytic machinery, 
which recruits receptor clusters into clathrin-coated pits and the membrane 
invaginations followed by vesicle scission forming cargo-containing receptors. 
GTPase dynamins are involved in constriction and fissions of vesicle stalks, 
cooperating with Rab family proteins (Mosesson et al., 2008, Zerial and McBride, 
2001). In order to assess if the discrepancy in AKT hyperactivation is due to EGFR 
trafficking, we used dynasore, a cell permeable inhibitor of dynamin to inhibit 
clathrin-mediated endocytosis. Indeed, dynasore inhibited EGFR endocytosis in 
both control and SPRY2 KD cells. Significantly, EGF induced activation of p-AKT 
in SPRY2 KD cells was abolished, confirming the importance of endosomal EGFR 
in promoting PI3K/AKT signalling (Figure 4.1.3). Altogether, loss of SPRY2 
promotes rapid internalisation and sustained accumulation of intracellular EGFR 
in response to EGF stimulation to enhance AKT activation in SPRY2 KD cells. 
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4.2 SPRY2 KD increases EGFR endocytosis via p38 in a PI3K 
dependent manner 
P38 is a key regulator of EGFR and implicated in phosphorylation of EGFR 
at Ser-1046/1047, which is closely linked to internalisation of the receptor 
(Nishimura et al., 2009). Furthermore, Zwang and Yarden proposed that chronic 
activation of p38 facilitates accumulation of EGFR in the endosomal 
compartments and aids tumour cell survival (Zwang and Yarden, 2006). We also 
observed an elevated phospho-p38 level in SPRY2 KD cells in the Human 
Phospho-kinase array in Figure 3.2.1.  This was further confirmed by the Western 
blot analysis in SPRY2 KD DU145 cells. Phosphorylation of EGFR and p38 were 
increased at both 15 and 30 minutes following stimulation with EGF in SPRY2 KD 
cells (Figure 4.2.1). In order to examine the role of p38 in terms of EGFR 
signalling and its downstream signalling in SPRY2 KD cells, cells were treated 
with p38 inhibitor SB203580, which is a pyridinyl imidazole derivative. The 
fluorine in the SB203580 compound interacts with ATP binding pocket in p38 
MAPK, which inhibits AKT binding (Gum et al., 1998).  
First of all, the inhibitory efficacy of SB203580 was examined, Western 
blot showed a decrease in phosphorylation of ATF2 in both control Nsi and SPRY2 
KD cells in the presence of the inhibitor. Transcription factor ATF2 is a direct 
downstream target of p38. Next, we observed a reduction in phosphorylation 
levels of EGFR and AKT when treated with the inhibitor in both Nsi and SPRY2 KD 
cells (Figure 4.2.2). Treatment with SB203580 decreased cell growth by over 30% 
(from 40% to <10%, or 4 fold reduction), compared with vehicle control sample in 
SPRY2 KD cells. The Nsi control cells also showed a reduction in proliferation 
with a fall of just over 10% (or 2 fold) in growth rate following inhibitor 
treatment (Figure 4.2.3). Furthermore, cells were also transfected with p38 
siRNA and Western blot analysis showed lower p38 expression level in both Nsi 
and SPRY2 KD cells compared to the negative control lanes. The growth rates 
were reduced to similar level seen with the p38 inhibitor treatment samples 
(Figure 4.2.4). 
 
 
   68 
 
 
 
 
 
 
 
 
 
 
 
 
 
   69 
 
 
 
 
 
 
 
 
 
 
   70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   71 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   72 
In order to examine the effect of SB203580 in EGFR internalisation, cells 
were pre-treated with p38 inhibitor and internalisation assay was performed 
using ELISA assay. The effect of inhibition on EGFR internalisation was observed 
from 15 minutes in SPRY2 KD cells, but EGFR internalisation was not affected in 
Nsi control cells at both time points (Figure 4.2.5). It is reasonable that as there 
was not much active p-p38 detected in the western blot analysis, we may expect 
that p38 inhibition would not affect the amount of internalised EGFR in Nsi 
control cells. However, at 30 minutes EGF treatment, there were a 20% 
reduction of EGFR internalised in SB203580 treated SPRY2 KD cells compared to 
the vehicle treated cells. In addition, the localisation of EGFR was visualised in 
cells treated with the p38 inhibitor using confocal microscopy. We transfected 
cells with EEA1-GFP plasmid to label early endosomes, and cells were treated 
with vehicle or p38 inhibitors prior to IF analysis. Similarly, there was a notable 
reduction in endosomal EGFR in inhibitor treated SPRY2 KD cells compared to 
vehicle treated cells (Figure 4.2.6). These results indicated that cooperation 
between activated p38 MAPK and loss of SPRY2 in EGFR signalling cascades play 
a critical role in the trafficking of the receptor and consequently led to 
uncontrolled PI3K/AKT activation. To understand the crosstalk between PI3K and 
p38 MAPK, we used PI3K/AKT inhibitor, LY294002, to examine the 
phosphorylation of EGFR and p38. The PI3K inhibitor abolished both EGFR and 
p38 phosphorylation in Nsi and SPRY2 KD cells (Figure 4.2.7). Furthermore, loss 
of SPRY2 in PTEN null PC3 cells results in rapid degradation of EGFR and 
subsequently no difference in PI3K/AKT activation observed between SPRY2 KD 
and Nsi control cells (Figure 4.2.8). We concluded that upon ligand binding to 
EGFR, this leads to enhanced activation of PI3K/AKT in SPRY2 KD cells, which in 
turn phosphorylates p38 MAPK. Consequently EGFR phosphorylated at serine and 
threonine sites enhances internalisation and continuous signalling in a positive 
feedback loop in a PTEN dependent manner.  
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4.3 EGFR cooperates HER2 trafficking but not HER3 
Abnormal EGFR trafficking and its downstream signalling in SPRY2 KD cells 
indicated the potential use of EGFR tyrosine kinase inhibitors, such as gefitinib 
(also known as Iressa). Surprisingly, SPRY2 KD cells showed significant survival 
advantage over Nsi control cells upon treatment with gefitinib. Hetero-dimer 
formed by EGFR and other HER family members including HER2 and HER3 may 
confer a selective growth advantage and can lead to resistance to selective 
tyrosine kinase inhibitor such as gefitinib (Tomlins et al., 2005). We investigated 
the involvement of HER2 in EGF stimulated cells. Interestingly, SPRY2 KD cells 
respond to EGF treatment with enhanced and sustained phospho-HER2 levels 
(Figure 4.3.1).  Hence, lapatinib, a dual inhibitor of both EGFR and HER2, was 
examined to assess the ability to inhibit SPRY2 KD cell growth more efficiently 
than gefitinib. Indeed the anti-mitotic effects of lapatinib were very comparable 
in both control and SPRY2 KD cells. There is over 30% reduction compared to 
vehicle treated cells, and more than 25% reduction of cell proliferation was 
observed compared to gefitinib treated cells. Furthermore, heregulin activated 
both HER3 and HER2 in DU145 cells, but only HER2 activation and cooperation 
were observed in the presence of EGF not HER3. There were similar levels of 
AKT phosphorylation in both Nsi and SPRY2 KD cells when stimulated with 
heregulin. Whereas EGF stimulates more AKT in SPRY2 KD cells, which may be 
attributed to the trafficking mediated by EGFR and HER2 activation (Figure 
4.3.2). This suggests in spite of functional HER3 in DU145 cells, only EGFR and 
HER2 heterodimers contributed to the enhanced cell growth in the presence of 
EGF in SPRY2 KD cells.  
There are multiple pieces of evidence to suggest a critical role for EGFR 
and HER2 in PC cell proliferation and invasion, especially castration-resistant 
disease (Zhan et al., 2006, Mellinghoff et al., 2004). In order to assess the 
kinetics of HER2 trafficking in EGF stimulated cells, the internalisation assay and 
Neutravidin immunoprecipitation (IP) were performed to pull down internalised 
proteins with NHS-S-S-biotin label. The biotinylated proteins were pulled down 
with NeutrAvidin agarose. The neutravidin beads IP internalised proteins, which 
were labelled at the cell surface with biotin in the beginning of the experiment. 
The IP results show clear increase of HER2 accumulation in SPRY2 KD cells 
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following EGF treatment at 60 minutes.  Whereas, there were surface HER3 
labelled with the biotin, but no endosomal HER3 detected in Nsi and SPRY2 KD 
cells (Figure 4.3.3). This supports the observation that HER3 was not significantly 
activated upon EGF stimulation. 
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SPRY2 expression was characterised in two independent PC cohorts in the 
format of tissue microarray (TMA).  The TMA included 202 cases of PC and 107 
cases of benign prostatic hyperplasia (BPH) as controls. Patients with reduced 
SPRY2 expression were stratified according to the HER paralogue expression 
status: those patients with HER2 positive disease have significantly poorer 
survival outcomes compared with those with HER2 negative disease (Log rank: 
p=0.014) (Figure 4.3.4). The IHC staining of human prostate tissue showed 
membrane and cytoplasmic HER2 immunoreactivity. None of the other members 
of the ErbB receptors including HER3 and HER4 showed any association with 
patient outcome. Since the interaction between RTK trafficking and SPRY2 loss 
occurs in a PTEN dependent manner, we segregated TMA into two groups, 
moderate and low PTEN expression. Moderate indicates PTEN expression was 
below median of BPH but above median of the cancer population. Low 
expression was relatively less PTEN expression than median score in cancer 
samples, which meant it included a histoscore of zero. The correlation analysis 
indicated a significant positive association between cytoplasmic HER2 and p-AKT 
among patients with moderate PTEN expression level, but p-ERK1/2 correlation 
is not significant (n=110), emphasising the importance of p-AKT in prostate 
carcinogenesis. Moreover, SPRY2 negatively correlated with both cytoplasmic 
and membrane HER2 and p-AKT, the association between SPRY2 and p-ERK1/2 
was not significant. Interestingly, the association between SPRY2 and p-AKT was 
lost in the low PTEN expressing PC (p=0.589, n=110) (Table 4.1). These TMA data 
suggests the in vitro hypothesis that loss of SPRY2 leads to hyperactivation of 
PI3K/AKT via RTK trafficking in a PTEN dependent manner and promotes PC 
development.  
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4.4 Summary and discussion 
The binding of ligands to EGFR leads to homo- and hetero-dimerization 
with members of the HER kinase family (Voeller et al., 1997). Interestingly, we 
observed the involvement of HER2, but not HER3, in the flow of EGFR 
trafficking; further contributing to enhanced RTK mediated intracellular 
signalling. P38-mediated phosphorylation of EGFR can then evade receptor 
degradation to produce sustained and enhanced signalling at the endosomes. 
Consistent with our findings, Zwang and Yarden (Zwang and Yarden, 2006) also 
postulated that chronic stress induced p38 activation either intrinsically in in 
vivo growth or associated with treatment such as cytotoxic dugs can enhance 
EGFR localisation to the endosomes with a pro-survival effect. In our PC TMA 
cohorts, reduced SPRY2 and upregulated p-AKT was significantly associated, but 
not with ERK activation, suggesting specific oncogenic choice for the cancer with 
SPRY2 loss. Interestingly, the PTEN status is crucial for such association, since 
among the PTEN negative tumours (histoscore zero) showed no correlation 
between low SPRY2 and activation of AKT.  In conclusion, complex interactions 
among RTKs and their downstream effectors exhibit fine regulation of the 
signalling networks to involve distinct signalling molecules, which may represent 
important targets for developing treatment in the context of personalised 
medicine. 
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5 Low SPRY2 and PTEN as biomarkers for PC responsive to 
PI3K inhibitor therapy 
Accumulating genetic evidence and cancer research suggest that the 
PI3K/AKT signalling cascade is pivotal in cancer initiation and growth. In 
prostate cancer, the main reason for abnormal activation of PI3K/AKT activation 
is related to the loss of PTEN including haplosufficiency and biallelic loss. 
Activation of RTKs also accounts for another important mechanism for the 
activation of PI3K/AKT in cancer. Briefly, activation of the PI3K/AKT signalling 
pathway often results from RTK (Roche et al., 1998). PI3K is a heterodimer 
consisting the p85 regulatory subunit and the p110 catalytic subunit. The 
regulatory domain directs the translocation of PI3K to the plasma membrane, 
while the catalytic domain phosphorylates PIP2 (phosphatidylinositol-4,5-
bisphospate) at the plasma membrane, which is part of the membrane 
compartment, to generate the second messenger molecular PIP3 
(phosphatidylinositol-3,4,5-trisphospate). The production of PIP3 leads to the 
activation of PI3K and downstream signalling including PDK1 (phosphoinositide-
dependent protein kinase1) and AKT through physical interaction (Engelman, 
2009). Several small molecules are developed to inhibit PI3K/AKT signalling 
including dual PI3K/mTOR inhibitor, PI3K inhibitor, AKT inhibitors and mTOR 
inhibitors. Unlike breast and lung cancer, the amplification of HER2 and 
mutation of EGFR are rare in prostate tumours. Yet, the tight spatial and 
temporal regulators of RTKs including SPRY2 are often deregulated in prostate 
cancer. Loss of SPRY2 in DU145 cells showed hyperactivation of PI3K/AKT in 
response to EGF stimulation. In addition, reduction of SPRY2 expression in 
prostate cancer cells exhibited rapid EGFR trafficking along with HER2, which 
led to the enhanced downstream signalling cascades including PI3K/AKT. In this 
study, the effect of a dual inhibitor PI103 was investigated in Nkx CRE Spry2+/- 
Ptenfl/+ mouse model described in Chapter 3. 
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5.1 PI3K inhibitor reduced SPRY2 KD cell lines growth and 
invasiveness 
As PI3K plays an important role in cancer biology, much interest has been 
generated to develop inhibitors as potential therapeutic agents. The 
understanding of the PI3K crystal structure has led to the design of small 
molecules including well-known compounds LY294002 and wortmannin. LY294002 
has been shown to inhibit PI3K more selectively than other protein kinases 
including EGFR and protein kinase C (Vlahos et al., 1994). In spite of antitumour 
effects of LY294002 in in-vitro and in-vivo models, its toxic side effects and poor 
solubility prevented the compound from entering clinical trials. As a laboratory 
cell based reagent, LY294002 is a useful tool to understand the function of PI3K 
in tumorigenesis. Furthermore, MAPK inhibitor PD098059 is also used to study 
the function of ERK1/2 in SPRY2 KD cells. The compound can inhibit MEK1 direct 
upstream of ERK1/2. 
Our working model is that loss of SPRY2 interacts with abnormal RTK 
signalling to drive PI3K/AKT hyper-activation mediated prostate carcinogenesis. 
Therefore, to test the significance of PI3K/AKT signalling, SPRY2 KD DU145 cells 
were treated with the PI3K inhibitor LY294002 and studied in proliferation and 
invasion assays. SPRY2 KD DU145 showed significantly reduced growth and 
invasion in the presence of LY294002. In contrast, the MAPK inhibitor PD098059 
did not have any effects (Figure 5.1.1).  
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5.2 SPRY2 and PTEN mouse model to identify PI3K inhibitor 
responsive prostate tumours 
In the Nkx CRE Spry2+/- Ptenfl/+ mouse prostate model, high level of p-
AKT, but not phospho-ERK1/2, staining was evident in the prostate of 3 months 
old animals (Figure 5.2.1).  Hence, the in vivo significance of SPRY2 loss 
associated AKT activation was examined using the potent PI3K inhibitor PI103. 
The compound is a selective class I PI3K inhibitor (IC50=3 nmol/L) and is around 
200 fold more potent than LY294002 (IC50= 600 nmol/L). PI103 was also tested 
for the effect on other tyrosine kinases, a screen against over 70 protein kinases 
showed little or no inhibitory activity. In vitro studies with human cancer cell 
lines showed inhibitory effects on proliferation of prostate, lung, ovarian and 
colon cancer cell lines (Carracedo et al., 2011b).  
In Nkx CRE Spry2+/- Ptenfl/+ mice the prostate tumour was palpated in the 
mouse model (10-11 months). PI 103 was injected daily 50 mg/kg intra-
peritioneal (ip) for 4 weeks, when tumours were apparent. The prostatic 
epithelium showed significantly fewer Ki67 positive cells (Figure 5.2.2), which is 
indicative of reduced proliferation. When compared to vehicle control treated 
mice, using a combination of western blotting and immunohistochemistry (IHC) 
experiments, p-AKT level was significantly reduced following PI3K inhibition. The 
H&E staining confirmed the presence of aggressive tumours in the vehicle 
treated mice (10-12 months). In contrast, PI103 treated animals, the prostate 
was filled with lymphocytic infiltration and the epithelial cells retained 
differentiated structure with a glandular architecture (Figure 5.2.3). It is worth 
noting that, even in the presence of increasing tumour bulk and invasion, these 
tumours retained their PTEN expression as shown by western blot analysis and 
IHC staining. PTEN immunoreactivity was observed at high level in lymphocytes 
(Ly) and at relatively lower level in the epithelial (Ep ) cells (Figure 5.2.4), thus 
excluding the involvement of de novo loss of the remaining PTEN allele. 
Prostatic lesions in these animals following PI 103 treatment were noticeably 
cystic (Figure 5.2.3) when compared to the solid nature of tumours in control 
treated animals (n=6). Hence, the lymph node status was used as an endpoint to 
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test the potential role of PI3K signalling in PC progression. In the cohort of 
Spry2+/- Ptenfl/+ mice studied, 3 of 4 animals treated with vehicle control 
developed metastatic lymph node lesions with evidence of androgen receptor 
expression. However, none of the four PI 103 treated animals developed 
metastatic nodal disease (p=0.025 Figure 5.2.5). Furthermore there was no 
change observed in phospho-ERK1/2 level in prostates of both treated and 
untreated animals (Figure 5.2.4). Enhanced apoptosis as illustrated by pyknotic 
and roughly rounded nuclei on TUNEL assay was also observed in PI 103 treated 
tumours (Figure 5.2.6). Furthermore, EGFR staining showed cytoplasmic and 
plasma membrane localisation in the vehicle treated prostate tissue, whereas 
the PI3K inhibitor treated tissue showed very little or no immunoreactivity of 
EGFR (Figure 5.2.7). In summary, the potent PI3K inhibitor significantly reduced 
tumour burden in Spry2+/- Ptenfl/+ mice, which suggested enhanced PI3K/AKT 
signalling plays a key role in PC driven by SPRY2 and PTEN loss.  
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5.3 Summary and discussion 
Recent evidence suggested combinatory targeted therapies could be more 
effective. For instance, MAPK and PI3K/AKT are simultaneously and 
synergistically activated in a PTEN+/- mouse prostate model (Gumerlock et al., 
1997). Our genetically modified (Nkx Cre Spry2+/- Pten+/-) mouse model showed 
evidence of PI3K/AKT hyper-activation, without MAPK activation, in the prostate 
and enhanced capability to develop metastatic nodal disease by 12 months. 
Significantly, the PI3K inhibitor PI103 exerted a dramatic inhibitory effect on the 
growth of nodal metastasis. In addition, the reduction of SPRY2 expression has 
been associated with high-grade prostate tumour, and patients often are treated 
with androgen depletion therapy. Combination of PI3K and androgen inhibition 
strategies may delay the onset of androgen independent disease progression. 
Hsieh and his colleagues suggested the importance of 4EBP-elF4E in translational 
components and as a potential target in AKT-mediated lymphoma and 
rapamycin-resistant tumours (Hsieh et al., 2010). Indeed, as PI3K/AKT are 
important upstream kinases, there are many downstream targets that may need 
further assessment for potential therapeutic strategies. 
Taken together, the selective activation of PI3K/AKT associated with 
SPRY2 loss in the context of PTEN insufficiency is important in prostate 
carcinogenesis: PI3K/AKT function enhances EGFR/HER2 signalling; PI3K/AKT 
promotes a proliferative and an invasive phenotype in vitro and in vivo; 
suppression of PI3K/AKT function reverse the above in vitro and in vivo 
phenotype; and finally, upregulated p-AKT expression was closely associated 
with reduced SPRY2 expression in clinical PC.  
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Chapter 6. SILAC analysis of SPRY2 interacting 
partners 
   100 
6 SILAC analysis of SPRY2 interacting partners 
In the last few decades, there has been an explosion of information and 
understanding in human genetics, which has given biologist a great insight into 
what we are made of and particularly be able to pinpoint many forms of 
diseases. No doubt, the genetic information reveals generally mutations, copy 
number changes and level of mRNA particularly in tumour biology, which has 
greatly improved prognosis and therapy. There are significant gap in our ability 
to translate tumour biology information into clinical application aimed for better 
patient proteome. The majority of enzymatic reactions are carried out by 
various proteins in the cell, and proteins undergo many post-translational 
modifications, compartmental trafficking, physical interaction with other 
partners and degradation. These processes are tightly controlled via many forms 
of feedback and signalling networks. Recently, many novel technologies have 
been developed to study the behaviour of proteins in a high throughput manner, 
namely proteomics. In tumour biology, complementary to genomic knowledge 
the global profiling of the protein pattern can be studied to compare normal and 
diseased conditions, in the hope of identifying molecular markers in order to 
elucidate disease mechanisms, including the initiation and progression of the 
disease. 
At present there are two types of labelling protocols commonly used in 
mass spectrometry (MS), including biological and chemical incorporation. The 
biological labelling of the proteins in the cell is achieved by adding stable 
isotope-containing anabolites to the media for cells to grow in tissue culture and 
this approach is used in this project. The purpose of using stable isotopes (13C, 
15N, 2H) is that the MS quantitative analysis of protein/peptides can distinguish 
between test samples by comparison of distinct molecular mass peaks of the 
labelled proteins, which gives a relative ratio of abundance of the different 
labelled isotopic forms present in the various test samples.  
Typical SILAC MS is achieved by culturing two /three groups of cells in 
culture media containing ‘light’, ‘medium’, and ‘heavy’ labelled amino acids 
(aa) (often with lysine and arginine). Since these aa are not synthesised by the 
cells, the labelled aa are incorporated into the cell in approximately 5 doubling 
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time. The SILAC method is a straightforward and efficient comparison of 
chemical incorporation, because there is no need to remove additional labels 
from the media or involve multiple steps for the labelling. In terms of signal-to-
noise quantitative analysis still require further development in future MS 
instrument and methodology. The samples in this project are prepared using the 
whole cell lysates, which means the quantification of the protein change may 
not capture the accurate interactions due to the disruption and dilution of the 
native conditions, particularly for those interactions, which occur in different 
intracellular compartments. To date there are different methods in quantitative 
proteomics, which have their advantage and limitations. Inevitably the global MS 
analysis will provide an enormous volume of quantitative data, although the 
ability to filter out specific/useful information would be the challenge in the 
future when the MS becomes a routine technique. 
In this project, GFP-tagged SPRY2 is transiently overexpressed in prostate 
cancer cell lines, and SPRY2 interaction proteome studied following EGF 
stimulation, which may give an insight into the mechanisms of SPRY2 
involvement in RTK signalling and trafficking. Potential interaction partners of 
SPRY2 may give better understanding of how SPRY2 exerts its inhibitory action, 
and consequently may help us to identify potential targets involving SPRY2 loss 
in carcinogenesis. Particularly in the presence of EGF, we have shown that loss 
of SPRY2 enhances prostate cancer development through EGFR/HER2 activation. 
An overview of the experimental design is shown in Figure 6.1.1. 
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6.1 Generation of SPRY2 overexpression model 
In order to further understand the action of SPRY2 in prostate 
carcinogenesis, endogenous SPRY2 IP was performed in DU145 cells. Firstly, the 
SPRY2 antibody was crosslinked to agarose beads and titration experiment was 
carried out with increasing volume of agarose beads. Western blot analysis with 
post IP supernatants (S) and IP sample indicated that 3 µl of beads volume is the 
optimal condition (Figure 6.1.2). Up to 1 µl beads volume, the level of SPRY2 in 
supernatants was still higher than in the post IP supernatants following 
incubation with 3-10 µl beads, although the non-specific signals were also 
weaker.  Hence, 3 µl beads per 2 mg of proteins were chosen for the future IP.  
For MS analysis, 106 cells were seeded and lysed on a 15 cm diameter dish 
and the protein concentration was determined using BioRad and Bradford assay. 
Samples were run on a 10% SDS-PAGE gel (Invitrogen), and the protein bands 
were visualised with Simply BlueTM SafeStain (coomassie blue staining kit) (Figure 
6.1.3). Even with optimised beads volume, there are many non-specific bands in 
beads alone lane, which was IP with beads without primary antibody crosslink. 
The SPRY2 protein bands were expected to be the most prominent in the IP lane, 
but this was not observed. Nonetheless, there was a double band at 43 kDa 
marker, which was identified as SPRY2 with MS. However the list of proteins 
pulled down were mostly nonspecific or mostly bead specific namely beadome 
including actin and actin related proteins. 
It is reasoned that the amount of SPRY2 in DU145 are limited and the 
primary antibody may not be as specific as we wished for IP. Next, the flag-
tagged SPRY2 plasmid was used to transiently transfect prostate cancer cell lines 
to increase the amount of SPRY2 expression level, and to overcome the 
difficulties. The efficiency of the plasmid transfection was assessed using IF, the 
endogenous SPRY2 showed punctuated staining near perinuclear localisation. In 
contrast, the flag-tagged SPRY2 localised all over the cytoplasm of the cell, with 
no specific localisation (Figure 6.1.4). In addition, SPRY2 antibody was not able 
to recognise the Flag-tagged SPRY2, since the endogenous SPRY2 signal was not 
overlapping with Flag signal. It may be due to the fact that Flag was tagged on 
the N-terminus of SPRY2 protein, where SPRY2 antibody recognises the protein. 
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The Flag IP was performed with caution, since SPRY2 expression seems 
overwhelming. As expected, the MS identified many Flag-bead specific proteins, 
with the most abundant protein identified to be SPRY2. In order to overcome 
such problem, GFP tagged SPRY2 plasmid was generated by inserting SPRY2 
sequence into pEGFP-C1 plasmid (Figure 6.1.5). Cells were transfected with 
pEGFP-C1 as control or GFP-SPRY2 plasmid, and visualised under the microscope. 
Interestingly, SPRY2-GFP localised to the peri-nuclear region, similar to 
endogenous SPRY2 (Figure 6.1.6). The transfection rate was only between 20-
30%, and the transfection reagent lipofectamine 2000 was toxic. Prior to the MS 
quantification, the samples were analysed by western blot. GFP and GFP-tagged 
SPRY2 were detected in whole cell lysates (WCL) samples lane 1 and 2 
respectively in Figure 6.1.7. The efficiency of GFP pull down was tested with 
post IP WCL, which was collected after separation of beads from the lysates. As 
expected, the GFP-SPRY2 transfected sample (2) had reduced amount of SPRY2 
compared to the initial WCL. In the IP sample, the empty vector and GFP-SPRY2 
lanes were confirmed to have high levels of GFP and GFP tagged SPRY2 
respectively. The endogenous SPRY2 was detected in all lanes except in the 
negative control IP sample. Furthermore, a positive interaction partner of SPRY2 
was assessed. It is reported that both SPRY2 and SPRY4 directly binds to wild 
type BRAF (not V599E mutant) and interferes with MAPK signalling cascades 
(Lampugnani and Dejana, 2007). BRAF was detected across all of the cell lysates 
with weak signal, and the GFP-SPRY2 IP sample showed the strongest band, 
indicating the interaction between exogenous GFP-SPRY2 and BRAF. These 
results suggested that GFP-tagged SPRY2 transfection system could be used for 
SILAC MS/MS analysis. 
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6.2 Analysis of SILAC mass spectrometry 
Firstly, PC3 cells were passaged in culture media containing isotope labels 
shown in Table 2.3. After 5 passages, the whole cell lysates were collected and 
the incorporation of the isotopes assessed. Such growth media did not show any 
detrimental effect on cell growth and morphology. The samples were prepared 
as illustrated in Figure 6.1.1, the protein sequences of the GFP-tagged SPRY2 is 
shown below (Figure 6.2.1). For the negative control, the empty vector pEGFP-
C1 was transfected. Both samples were run on a SDS-PAGE gel and stained with 
coomassie blue. As expected, GFP-SPRY2 (61 kDa) was the most prominent band 
was between 72 and 55 kDa. The negative control lane had a strong band around 
34 kDa marker, which was the GFP tag alone (Figure 6.2.2). The gel was cut as 
indicated, digested with trypin, and performed LC MS/MS analysis. The MS 
analysis identified around 90 different proteins. GFP beadome, and proteins 
identified in the negative control samples were excluded from the candidate 
lists. For example, variants of heat shock 70KDa protein, cytokeratin 8 and 18, 
and ubiquitin are most commonly detected in GFP pull down (Trinkle-Mulcahy et 
al., 2008). Indeed these proteins were identified in both empty vector and GFP-
SPRY2 IP samples. In addition, there are also sepharose bead associated non-
specific binders, including cofilin, filamin, vimentin, plectin, actin, myosin, and 
tubulin, which are cytoskeletal, motility or structural protein families. Also, it is 
reported that various histones, heat shock proteins, ribosomal proteins, hnRNP 
proteins and translational factors are mostly pulled down with sepharose beads 
IP. Considering the non-specific binding proteins, most of proteins identified 
from PC3 cell line SILAC IP were bead related protein, not SPRY2 interaction 
partners. It was thought that in vitro findings from Chapter 3 explains non-
inclusive results from the SILAC IP, since PTEN null PC3 cells had showed no 
effect when SPRY2 expression level was reduced. Thus, overexpression of SPRY2 
may not be functional in PTEN negative cells. 
In contrast to PC3, DU145 (PTEN positive) SILAC IP results revealed a 
different list of proteins as candidate interaction partners. Although GFP beads 
related non-specific binding proteins were similar as mentioned above. There 
were interesting potential authentic interacting partners of SPRY2, including 
creatin kinase B, serine/threonine-protein phosphatase 2A (PP2A) 65 kDa 
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regulatory subunit A alpha isoform, and LIM domain only protein 7. Lao and his 
colleagues reported that SPRY2 co-IP with PP2A and regulates downstream of 
FGFR signalling cascade (Lao et al., 2007). In addition, there were few 
candidates identified including creatin kinase B (CKB), LIM domain only protein 7 
(LMO7), pyruvate kinase isoenzyme M1/M2 (PKM2), and Ras GTPase-activating 
protein binding protein 1 (G3BP1) (Table 6.1).  
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6.3 Validation of its interaction partners 
In order to validate the candidates identified from the MS analysis, the 
potential interaction partners were validated with western blots. Whole cell 
lysates were collected before and post IP, which is shown in the Figure 6.3.1. 
The possible candidates suggested by the SILAC IP were PP2A (protein 
phosphatase 2A), PKM2 (pyruvate kinase isoenzyme M1/M2), CKB (creatin kinase 
brain type) and clathrin heavy chain. There were difficulties to obtain 
commercially available antibodies, which can be used for western analysis, for 
some of candidates in the lists. PKM2, CKB and clathrin were detected in WCL 
and post IP WCL, and also in the negative control lane. The GFP beads strongly 
bind to the proteins, thus these were considered as non-specific binding, namely 
beadome. These proteins were detected in the SPRY2-GFP IP sample lane with 
weaker signal compared to negative control. Interestingly, PP2A is only detected 
in SPRY2 IP lane and WCL, but not in the negative control lane. This confirms 
that PP2A is the true binding partner of SPRY2. The peptides were identified in 
MS/MS are highlighted in the Figure 6.3.2. It has been reported that upon FGF 
stimulation SPRY2 directly binds to PP2A and the binding sites involving SPRY2 
are tyrosine 55 residue (Lao et al., 2007).  
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6.4 Summary and discussion 
Various proteomic techonologies particularly SILAC MS and pre-existing 
cell biology knowledge provide many opportunities and questions to be asked in 
post genome era. The project involving endogenous SPRY2 IP demonstrated the 
difficulties underlie in cellular and technical aspects. It was due to the fact that 
the level of SPRY2 expression is not abundant enough to pull down for MS 
analysis. Kriegsheim and his colleagues (von Kriegsheim et al., 2009) managed 
for the first time to IP endogenous ERK, which is often ubiquitously expressed. 
Also commercially available antibodies for SPRY2, which is an affinity isolated 
polyclonal antibody (Sigma), may not be as specific and effective as monoclonal 
antibodies used in ERK IP.  
The separation of specific protein interactions from bead proteomes is a 
major challenge in the field. There are over 30 proteins pulled down as GFP 
specific binding partners and several hundreds of proteins interact with 
sepharose beads (Trinkle-Mulcahy et al., 2008). These proteins are mainly 
cytoskeletal, structural and motility proteins, which are often considered as the 
most abundant proteins in a cell. In order to increase the amount of protein 
expression, plasmids are used to express the protein of the interest. As 
described in Chapter 6, Flag and GFP tagged SPRY2 were overexpressed in 
prostate cancer cell lines. The GFP-Trap system was more effective compared to 
Flag pull down. GFP pull down validated BRaf as a positive control but not in 
Flag-tagged SPRY2 IP. In addition, the localisation of the tagged SPRY2 seemed 
more specific with GFP tag rather than Flag. Transient transfections system with 
plasmid should be used with consideration of other side effects including 
overwhelming the cell with the protein of interests, which is not physiological. 
Thus the effect and potential interaction candidates could well be non-
physiological or non-specific. Furthermore, common tags including GFP and Flag 
could affect the host protein folding, behaviour or its binding partners. 
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Chapter 7. Discussion 
   121 
7 Discussion 
Recent advances in global genomic profiling have generated vast amounts 
of data from cancer patients including prostate tumour, which has provided us 
with better understanding of carcinogenesis and confirming molecular 
abnormalities and revealing potential targets for therapy. Loss of PTEN plays a 
key role in PC progression, and is a hallmark of advanced disease. Indeed, cBio 
portal indicated that 16% of cases (n=194) either lost both copies or one copy of 
Pten alleles. As expected, almost half of patients have complete loss of Pten in 
patients (n=37) with advanced metastatic diseases (Taylor et al., 2010). The rest 
of metastatic disease still express PTEN, the interesting question is how these 
cancers become aggressive with PTEN retention. In this project, I examined the 
significance of regulatory components of the PI3K/AKT signalling particularly 
focused on SPRY2, which is known as a negative regulator of RTK cascades. 
Following the discovery of Drosophila SPRY as an antagonist of FGFR signalling 
pathway, many researchers have uncovered the role of mammalian SPRY family 
members in various cancer developments (Hacohen et al., 1998). Given the 
important role of RTK in normal and tumour development, no doubt SPRY 
proteins regulate various RTK including FGFR, VEGFR and EGFR in a temporal and 
spatial manner. However, the role of SPRY members particularly SPRY2, remains 
to be elucidated in cancer biology. In advanced metastatic PC, there are a total 
of 38% of cases with downregulation of SPRY2 expression. Interestingly, half of 
the cases have PTEN complete deletion, and the other half are with retention of 
PTEN expression (Figure 7.1). Considering PTEN is essential for SPRY2’s 
regulatory role, this project focused on the role of SPRY2 in EGFR with PTEN 
expressing PC.  
Firstly, in vitro cell line studies showed that stable KD SPRY2 leads to 
enhancement in cell proliferation and invasiveness in PTEN positive DU145 cell 
lines in response to EGF stimulation. Engagement of ligands to EGFR often 
results in MAPK and PI3K/AKT signalling activation to aid cell growth and 
movements. Interestingly, the human phospho-kinase array suggested that the 
exacerbated signalling activation in SPRY2 KD cells was associated with the 
hperactivation of PI3K/AKT. This project further investigated the potential 
mechanisms entailing RTK and the regulatory component of PI3K/AKT. Among 
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RTK family, ErbB family members including EGFR and HER2 involve complex 
compartment-specific signalling upon ligand binding. Internalisation assay 
indicated both EGFR and HER2 (not HER3) rapidly trafficking and retention at 
endosomal compartments resulted in enhanced downstream PI3K/AKT signalling 
in SPRY2 KD cells. Such trafficking and signal amplification in SPRY2 KD cells 
required the presence of PTEN expression. Furthermore, dissection of RTK and 
PI3K/AKT signalling cascades with various inhibitors including LY294002 and 
SB203580 confirmed the involvement of p38 serine/threonine kinase in 
protecting RTK from degradation and facilitating internalisation, which forms 
feedback forward loop described in Chapter 4. Thus PC cells are capable of 
utilising RTK signalling component without amplification or mutation of the 
receptors for cell growth unlike common amplification of HER2 in breast cancer.  
Secondly, Nkx Ptenfl/+ Spry2+/-mouse model developed aggressive PC 
around 10-12 months with mestastatic involvement of lymph nodes. Prostate 
tumour tissue collected from these transgenic mice showed hyperactivation of 
PI3K/AKT and enhanced cytoplasmic EGFR. This supports the hypothesis drawn 
from in vitro human cell lines. Reduction of SPRY2 expression was associated 
with enhanced activation of PI3K/AKT signalling cascades in response to EGF 
stimulation. EGFR and HER2 heterodimers showed rapid trafficking and 
amplification of the signalling via p38 and in a PTEN dependent manner (Figure 
7.2). In addition, the mouse model provided an experimental platform for 
testing chemotherapy strategies. In contrast to PTEN or SPRY2, it is much easier 
to target activated PI3K/AKT signalling pathways for therapy rather than trying 
to restore the lost tumour suppressor function. One of the major challenges in 
the clinical use of PI3K inhibitors is to identify patients with PC specifically 
driven by such molecular abnormalities. However, PC is a heterogeneous disease 
with complex genetic and epigenetic abnormalities, which are difficult to be 
fully represented in a single transgenic mouse model. Thus this study provides an 
important insight into potential strategies for developing future combinatorial 
therapeutic approaches. Of note, both in vitro cell model and preclinical mouse 
prostate tumour responded well to the treatment with the PI3K inhibitor PI103 in 
terms of inhibition of cell proliferation and invasiveness. It is worth considering 
the particular patient cohort with PC showing SPRY2 and PTEN along with 
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hyperactivation of PI3K/AKT. These patients may be responsive to targeted 
therapy to PI3K/AKT signalling. 
Thirdly, the human TMA data further confirms the important roles of 
PTEN, SPRY2 and RTK in PC development. Correlation analysis suggested a strong 
asscociation between SPRY2, HER2 and AKT. Loss of SPRY2 acts as a negative 
regulator of HER2 function and results in hyperactivation of AKT in prostate 
carcinogenesis. Given HER2 has no known intrinsic ability to bind to cognate 
ligands, its function relies on the formation of heterodimers with EGFR and 
HER3, and the significant correlation between cytoplasmic HER2 is concomitant 
with the importance of signal amplication via internalisation of the receptors. 
For future studies, there are PC patients with both PTEN completely loss and 
downregulation of SPRY2 (10/194), which may have different profile of abnormal 
molecular mechanisms contributing PC progression. Further research of in vivo 
models with homozygous deletion of Spry2 and Pten may give insight into other 
potential therapeutic targets for this particular subset of patient. 
Finally, cancer is generally believed to be a multistep genetic disorder 
(Potente et al., 2007). Either by loss of tumour suppressor gene or 
hyperactivation of specific oncogene, we have tried to restore, repair or 
inactivate these abnormal pathways. Abatement of certain oncogenic activity 
led to regression of tumours, so called tumour with oncogenic addiction. 
However, relapsed tumour with more aggressive phenotype is often observed 
within various cancers, which may be attributed to the pressure encouraging 
cancer cell evolution and adaptation. A recent popular topic is to understand the 
metabolic signature of tumour cells and find therapeutic targets. Whether the 
metabolic concept is merely another form of oncogenic addiction remains to be 
answered. In addition, it is clear that in addition to genetic alteration, there are 
other components essential for tumour maintenance including microenvironment 
surrounding cancer cells and cancer stem cells. Thus, there is neither a single 
model nor magic bullet in cancer biology. Given PC is an age related disease, it 
is clear that for PC the future goal of research is to delay the onset of the 
aggressive and metastatic form, which may allow patients to live and manage 
the disease with ease like diabetes. This may reduce PC related mortality and 
morbidity. 
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The graphic abstract illustrates the signalling network of EGFR and HER2, which 
occur at both plasma membrane and endocytic compartments. The trafficking of 
the receptors through EE (early endosome), LE (late endosome) and RE 
(recycling endosome) are critical for the maintenance and amplification of the 
downstream signalling outcome.
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